

---

**Current Appointments:**

01/2024-current	Senior Director (aka Associate Director) for Clinical Research, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah Professor of Medicine
07/2018-current	Professor, Department of Internal Medicine (Medical Oncology) Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
10/2017-current	Huntsman Cancer Institute (HCI) Presidential Endowed Chair of Cancer Research, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
07/2013-current	Director, Genitourinary Oncology, Division of Medical Oncology HCI/University of Utah, Salt Lake City, Utah
07/2013-current	Director, Center of Investigational Therapeutics, HCI/University of Utah.

**Past Appointments:**

04/2023-01/2024	Senior Director (aka Associate Director) for Clinical Translation, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
04/2021-04/2023	Senior Director for Clinical Research Innovation, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
10/2017-06/2021	Co-leader, HCI Experimental Therapeutics Program (CCSG Program) HCI/University of Utah, Salt Lake City, Utah (NCI-CCC)
10/2012-06/2019	Co-Leader, Urologic Oncology Multidisciplinary Program HCI/ University of Utah, Salt Lake City, Utah
07/2014-06/2018	Associate Professor of Medicine (tenured), Department of Internal Medicine (Medical Oncology) Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
07/2013-06/2017	Associate Director, Clinical Trials Office Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
07/2007-06/2014	Assistant Professor of Medicine (tenure track), Department of Internal Medicine (Medical Oncology) Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah

**Clinical Training:**

07/2004-06/2007	Fellow, Hematology/Oncology
-----------------	-----------------------------

07/2003-06/2004	University of Utah Huntsman Cancer Institute, Salt Lake City, UT Fellow, Geriatric Medicine (Geriatrics)
07/2001-06/2003	University of Iowa Hospitals and Clinics, Iowa City, IA Resident, Internal Medicine
07/2000-06/2001	University of Iowa Hospitals and Clinics, Iowa City, IA Intern, Internal Medicine Advocate Illinois Masonic Medical Center, Chicago, IL.

**Medical Education:**

02/1997-02/2000	MD, Medicine (Postgraduate diploma in Medicine) All India Institute of Medical Sciences, New Delhi, India
02/1990- 08/1995	MBBS (Bachelor of Medicine and Bachelor of Surgery) Assam Medical College, Dibrugarh, India

**ABIM Board Certifications:**

10/2008-12/2018	Diplomate (Board Certification) in Hematology
11/2007-12/2027	Diplomate (Board Certification) in Medical Oncology
12/2004-12/2014	Diplomate (Board Certification) in Geriatric Medicine
12/2003-12/2013	Diplomate (Board Certification) in Internal Medicine

**Licensure:**

2017-current	Utah State Medical License
2001-2004	Iowa State Medical License
2000-2003	Illinois State Medical License
1998-current	ECFMG - Physician (MD)
2017-2020	Controlled Substance (UT) - Physician (MD)
2016-2019	DEA Certificate (UT) - Physician (MD)

**Awards, Honors, and Recognitions:**

2025	Scholar Impact: h-index 88; i10-index 406; citations 390489
2025-Present	Chair, Prostate Cancer Foundation (PCF), Clinician-Industry Roundtable
2024	ASCO Advocacy Champion
2024-Present	Member, Scientific Program Committee, 2024 European Society of Medical Oncology (ESMO) Congress, Barcelona, Spain
2024	Poster Chair, GU, Prostate Track, European Society of Medical Oncology (ESMO) Congress, Barcelona, Spain
2023	Guy A. Zimmerman, MD, Faculty Mentoring Award, University of Utah Department of Internal Medicine, Salt Lake City, UT.
2023	Top Reviewer of 2022, Journal of Clinical Oncology (JCO), American Society of Clinical Oncology (ASCO)
2023	Fellow of the American Society of Clinical Oncology (FASCO)
2017-2023	Featured Voice #GU17, #GU18, and #GU19, #GU20, #GU22 at the 2017, 2018, 2019, 2020, and 2022 Genitourinary Cancer Symposium (aka ASCO GU), Orlando, FL and San Francisco, CA. February 2017, 2018, 2019, 2020, and 2022.

2021 Featured Voice 2021 ASCO Annual Virtual meeting #ASCO21

2021-2025 Editor in Chief: American Society of Clinical Oncology (ASCO) Daily news

2021 Reviewer of the Month (October 2021), European Urology

2021 ASCO Advocacy Champion

2020 Top Reviewer for 2020, European Urology Oncology (EUO)

2018 2017-2018 Outstanding Faculty Mentorship Award, Department of Internal Medicine, University of Utah, Salt Lake City, UT

2016 Chair, Prostate Cancer Session, 17<sup>th</sup> Annual Meeting of the Society of Urologic Oncology (SUO), San Antonio, TX, December 1, 2016

2014 National Cancer Institute (NCI): 2014 Cancer Clinical Investigator Team Leadership Award (3P30CA042014-25S2)

2014 Chair, Genitourinary (Non-prostate) Cancer Poster Highlights Session, American Society of Clinical Oncology (ASCO) annual meeting, Chicago, IL. May 30, 2014

2013 Chair, Oral Prostate Cancer Session, American Society of Clinical Oncology (ASCO) annual meeting, Chicago, IL. June 1st, 2013

2013 American Society of Clinical Oncology (ASCO) Medical Student Rotation (MSR) Mentor Award (for student from underrepresented population), 2013

2013 SWOG's top-accruing member institution for 2012-Nominated to receive the award at the SWOG spring meeting plenary session on behalf of University of Utah as the top accruer at the site

2013-Present National PI, NCI-CTEP trial: Phase 3, SWOG-1216 ((NCT01809691)

2010-2023 Leader of Early Therapeutics, Scientific Leadership Committee, South West Oncology Group (SWOG) - Committee for Genitourinary Cancers

2009 2009-2010 William D. Odell Young Investigator Award (“University of Utah Department of Internal Medicine-Outstanding Junior Faculty Award”)

2009 South West Oncology Group (SWOG) 2009 Young Investigator

2008 “Travel Award”: Radiation Therapy Oncology Group (RTOG) Medical Oncology Travel Award, RTOG Semi-Annual meeting in San Diego, California, January 17, 2008

2007 American Association of Cancer Research (AACR) Scholarship Award: for NCI Sponsored Molecular Biology in Clinical Oncology workshop, July 2007

2007 Fellow Research Award, 9th Annual Mayo Clinic Hematology/Oncology Fellow’s Research Symposium (17th Annual Mayo Clinic Hematology/Oncology Oncology Reviews), 2007

2003 Winner, Clinical Vignette Competition, American College of Physicians Annual Meeting, San Diego 2003

2003 Finalist, Research Poster Competition, American College of Physicians Annual Meeting, San Diego 2003

2003 Merck Travel Award, American College of Physicians Annual Meeting, San Diego, 2003

2001 Resident (PGY1) of the year. 2000-2001, 06/2001

1997 Ranked 5<sup>th</sup> in the All India Entrance Exam for Post-Graduation in Medicine

**Other Training and Certifications:**

- 2015 Participant, Inaugural Integrated Translational Science Center (ITSC) Workshop (Cold Spring Harbor Laboratory and SWOG, funded by the Hope Foundation), Branbury Campus, Cold Spring Harbor Labs, June 18 – June 20, 2015, Long Island, NY
- 2009 South West Oncology Group (SWOG) Young Investigator Training Course, 2009
- 2007 American Association of Cancer Research (AACR) and NCI sponsored “Molecular Biology in Clinical Oncology workshop”, Given Institute of the University of Colorado, Aspen, CO. July 2007
- 1999 Education Commission for Foreign Medical Graduates (ECFMG) Certification, Permanent validation, 11/1999

**Recent Grants and Funding (excluding funding for the clinical trials):**

1. 1R01CA281759-01 (NIH/NCI) Grant (mPI s: Neeraj Agarwal, Adriana Coletta). Period: 7/2023-06/2028. Total funding: \$3,370,430
2. 5P30CA042014-30 (NIH/NCI) Cancer Center Support Grant (PI: Cornelia Ulrich). Period: 5/09/1997-current. Role: Senior Director for Clinical Research
3. 5P30CA042014-30 (NIH/NCI) Cancer Center Support Grant (PI: Cornelia Ulrich). Period: 5/09/1997-4/30/2020. Role: Program Co-Leader, Experimental Therapeutics; Member, Protocol Review and Monitoring Committee
4. IIS Study: “Correlation of germ line mutations in DNA repair genes and treatment related outcomes in men with advanced prostate cancer”. PI: Neeraj Agarwal. Total funding (Astra Zeneca): \$60,000. 03/2017-03-2018
5. IIS Study: “Validation of genomic biomarkers or response to VEGFR-TKI in metastatic renal cell carcinoma and the development of a cell-free DNA assay to assess genomic biomarkers of treatment response”. PI: Neeraj Agarwal. Total funding (Pfizer): \$291,103. 08/2016-07/2018
6. 2014 National Cancer Institute (NCI): 2014 Cancer Clinical Investigator Team Leadership Award (3P30CA042014-25S2). Total award funding: \$100,000
7. R01CA172436 (NIH-NCI) Biomarkers of hormone therapy response in a multicenter prostate cancer trial. (PI: Amir Goldkorn). Role: Co-investigator (effort~4%)
8. PC101993 [Department of Defense (DOD) Prostate Cancer Research Program (PCRP)] - “Identification of Genes and Genetic Variants Associated With Poor Treatment Response in Patients with Prostate Cancer”. (PI: Lisa Cannon-Albright). DOD; W81XWH-11-1-0342. Total funding: \$894,706. Period: 09/30/2011-09/29/2013. Role: co-investigator (effort 8%)
9. U01AG034661-01 (NIH-NIA) Partnership for Anemia: Clinical and Translational Trials in the Elderly (PACTTE) Consortium (PI Harvey Cohen). Total funding: \$1,021,960.60 Period: 09/30/2009- 06/30/2015. Role: Co-Investigator (effort: 09/30/2009-06/30/2010: 7% per year; 07/01/2010-03/30/2011: 21% per year; 04/01/2011-09/30/2012: 5% per year)
10. Director’s Translational Research Initiative 2008, Huntsman Cancer Foundation. Total funding: \$40, 000. Period: 07/01/08-07/01/13. Role: Principle Investigator.
11. R21 (1R21CA135250-01) Biobehavioral Effects of Tai Chi Chih Among Elderly Cancer Survivors (PI: Anita Kinney). Total funding: \$529,631. Period: 09/30/2009-06/30/2011. Role: co-investigator (effort: 4%)

12. Cancer Control and Population Sciences (CCPS) FY11 Pilot Grant Program, Huntsman Cancer Foundation - “Evaluation of Patient and Provider Attitudes towards Genetic Prostate Cancer Risk Assessment and Corresponding Educational Needs”. PI: Neeraj Agarwal and Anita Kinney. Total funding: \$39,952. Period: 12/01/10 to 11/30/11. Role: Principle Investigator
13. Cancer Control and Population Sciences (CCPS) FY11 Pilot Grant Program, Huntsman Cancer Foundation - “Androgen Deprivation, Adrenergic Receptor Expression and Fatigue in Prostate Cancer “. (PI: Kathleen Light and Anita Kinney). Total funding: \$39,999. Period: 12/01/10 to 11/30/11. Role- Co-Investigator
14. Program in Personalized Health Care’s Human DNA Sequencing Grant Program, University of Utah - “Sequencing to Identify Predisposition Genes for Recurrent/Lethal Prostate Cancer”. (PI: Lisa Cannon-Albright). Total funding: \$40,000. Period: 11/01/2011 to 11/01/2012. Role- Co- Investigator
15. W81XWH-14-2-0189 [US Army Medical Research Acquisition Activity] – “The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)”. 11/01/2014 – 9/29/2017, John Hopkins University, Total Direct Cost Budget: \$192,220.07, Total Cost Budget: \$268,979.70

**Membership in Professional Societies:**

2005-Present	Member, American Society of Clinical Oncology (ASCO)
2007-Present	Member, American Association of Cancer Research (AACR)
2008-Present	Member, Southwest Oncology Group (SWOG) - GU Committee
2014-Present	Member, American Urology Association (AUA)

**Committee, Organizational, and Volunteer Service:**

**National/International:**

1. **Panel member**, National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline Panel for Kidney Cancer, 10/2008-present
2. **Panel member**, National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline Panel for Testicular Cancer, 10/2008-10/2016
3. **Member**, Southwest Oncology Group (SWOG) - Committee for Genitourinary Cancers. 01/2009-present
4. **Panel member**, National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline Panel for Bladder Cancer, 03/2010-present
5. **Leader of early therapeutics**, Scientific Leadership Committee, South West Oncology Group (SWOG) - Committee for Genitourinary Cancers. 04/2010-04/2023
6. **Member**, Conquer Cancer Foundation of ASCO- Grants Selection Committee, 06/2016-06/2019; 06/2021-06/2022
7. **Member**, American Society of Clinical Oncology (ASCO) Practice Guidelines Implementation Network (PGIN). 04/2017-2019
8. **Subject Matter Expert**, ASCO Advantage Program on Prostate Cancer, 06/2017
9. **Consultant (ad hoc)**, Oncology Drug Advisory Committee (**ODAC**), United States of America (USA) Food and Drug Administration (**FDA**), as a Special Government Employee (**SGE**). 08/20/2017-07/31/2025
10. **Faculty**, ASCO University, 2018

11. **Faculty**, SWOG Genitourinary committee new investigator workshop, 2019 SWOG spring meeting, San Francisco, CA. 04/2019
12. **Faculty**, 2019 ASCO grant writing workshop, 2019 ASCO Annual Meeting, Chicago, IL. 5/2019
13. **Subject Matter Expert**, ASCO Advantage Program on Kidney Cancer, 08/2019 and, 12/2019
14. **Member**, 2019 ASCO Quality Care Symposium News Planning Team, 09/2019
15. **Member**, ASCO Communications Committee, 01/2019-12/2021
16. **Member**, ASCO Genitourinary Cancer Guideline Advisory Group (GAG) to the Clinical Practice Guidelines Committee, 06/2020-06/2024
17. **Moderator**, U.S. Food and Drug Administration (FDA) Workshop: Clinical Trial Design for Non-Muscle Invasive Bladder Cancer (NMIBC), 11/2021
18. **Member**, 2025 European Society of Medical Oncology (ESMO) Scientific Committee
19. **Steering Committee and Panel Member**, 2023-2025 United States (US) Prostate Cancer Conference
20. **Panel Member**, Advanced Prostate Cancer Conference (APCCC), Lugano, Switzerland
21. **Member**, Vogelzang Scholar Selection Committee, SWOG, 11/2024-present
22. **Member**, ASCO Ed Book Editor-in-Chief Search Committee, 03/2025-06/2025

#### **Ad hoc Journal Reviewer (selected journals):**

British Journal of Cancer, British Journal of Urology (BJU) International, Cancer, Cell, Cancer Research Treatment Communications, Cell, Clinical Cancer Research (CCR), Clinical Genitourinary Cancer, European Journal of Cancer, European Urology Journals, JAMA Oncology, Journal of National Cancer Comprehensive Network (JNCCN), Journal of Clinical Oncology (JCO), Journal of Urology, Lancet, Lancet Oncology, Molecular Cancer Research, Molecular Cancer Therapeutics, Nature Medicine, New England Journal of Medicine (NEJM), Urologic Oncology: Seminars & Original Investigations.

#### **Editorial Roles with Journals:**

1. Editor in Chief: **ASCO Daily News** (06/2021-present)
2. Editorial Board Member, Journal of Clinical Oncology (**JCO**) (01/2020-12/2022)
3. Associate Editor: **ASCO Daily News** (01/2020-05/2021)
4. **Consulting editor: European Urology (2021- present)**
5. Section Editor (Genitourinary Oncology): **Cancer Treatment and Research Communications (Elsevier)** (01/2017- 06/2021)
6. Associate Editor: **Clinical Genitourinary Cancer Journal** (Elsevier) (2013-2021)
7. Chief Editor: GU Oncology, **Medscape Drugs & Diseases** (09/2016-03/2017)
8. Section Editor: GU Oncology, **Current Treatment Options in Oncology (Springer)** (01/2017-01/2018)
9. Guest Editor: **Urologic Oncology Seminars and Original Investigations** (06/2017)
10. Editorial Board Member: **European Urology Oncology** (07/2018- present)
11. Associate Editor: **Kidney Cancer** (IOS press) (11/2018- present)
12. Associate Editor: 2019 **GU ASCO** (genitourinary oncology symposium) **daily news**
13. Specialty Editor (Genitourinary cancers), **Cancer.Net of ASCO** (08/2019 – present)

**Other:**

1. **Member, Data Safety Monitoring Committee**, UTHSCSA 36911: Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial (Clinicaltrials.gov: NCT01157676)
2. **Invited Panelist**, MD Anderson Cancer Center sponsored “9th Annual Oncology Update: Advances and Controversies”, Park City, Utah. 01/18/2008
3. **Invited Panelist**, MD Anderson Cancer Center sponsored “8th Annual Oncology Update: Advances and Controversies”, Park City, Utah. 01/20/2008
4. **Grant Reviewer**, Scientific TOP programme, The Netherlands Organization for Health Research and Development. 09/2012
5. **Grant Reviewer**, Hope Foundation/SWOG Impact Award. 03/2015.
6. **Member**, MSCI Committee. Nick Frazier – M.S. Clinical Investigation candidate, Department of Bioengineering, USTAR- Ghandehari Group, University of Utah, Salt Lake City, Utah. 07/2014-06/2016
7. **Grant Reviewer**, Bladder Cancer Advocacy Network (BCAN) Young Investigator Award. 2016-2019
8. **PhD Thesis Reviewer**, Nazia Syed – Biochemistry and Molecular Biology. Pondicherry University, Pudhucherry, India. 06/2016
9. **Grant Reviewer**, National Cancer Institute (NCI), 2019 Cancer Clinical Investigator Team Leadership Award (CCITLA), 01/2019
10. **Grant Reviewer**, Rising Tide Foundation for Clinical Cancer Research (RTFCCR), Switzerland

**State/Institutional:**

1. **Co-Chair**, Clinical Research Executive Committee (CREC), Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
2. **Member**, Research Executive Committee (CREC), Huntsman Cancer Institute, Salt Lake City, UT.
3. **Member**, Protocol Review and Monitoring Committee (PRMC), Huntsman Cancer Institute, University of Utah, 01/2010-Present
4. **Member**, University of Utah School of Medicine Tenured and Clinical Faculty Review Committee, Department of Internal Medicine.2009-2018
5. **Member**, University of Utah School of Medicine, Admissions Committee. 08/2012-06/2014
6. **Member**, Physician Scientist Recruitment Committee, Huntsman Cancer Institute, University of Utah. 2014- Present
7. **Member**, Fellowship Research Curriculum Committee, University of Utah Hematology Oncology Fellowship Program. 2014-Present
8. **Director**, Center of Investigational Therapeutics (CIT), Huntsman Cancer Institute, University of Utah. 2017- Present
9. **Member**, Research Trials Review Committee (RTRC), Huntsman Cancer Institute, University of Utah. 05/2021-Present
10. **Member and School of Medicine Representative**, Conflict of Interest (COI) Committee, University of Utah, 10/2021-08/2025
11. **Mentor and Member**, Internal Advisory Committee (IAC), Huntsman Cancer Institute. 02/2023-Present

12. **Board Member**, Society of Utah Medical Oncologists (SUMO) Board, 2/2024-present

**Oral Presentation – First Author in ASCO/ESMO Meetings:**

1. **Oral Presentation, 2025 Genitourinary Cancer Symposium (GU ASCO)**, TALAPRO-2: Overall Survival Result of Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). San Francisco, CA. February 13-15, 2025
2. **Oral Presentation, ESMO Congress 2024**, Proffered Paper Session: Final Overall Survival Results: CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Barcelona, Spain. September 13-17, 2024.
3. **Oral Presentation, ESMO Congress 2024**, Education session: T-cell engagers in prostate cancer (special symposium on What's on the horizon for metastatic prostate cancer patients). Barcelona, Spain. September 14, 2024
4. **Oral Presentation, 2024 Genitourinary Cancer Symposium (GU ASCO)**, CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). San Francisco, CA. January 25-27, 2024
5. **Oral Presentation, ESMO Congress 2023**, Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study. Madrid, Spain. October 20-24, 2023
6. **Oral Presentation, 2023 ASCO Annual Meeting**, When More Is More: Treatment Intensification for Hormone-Sensitive Prostate Cancer. Chicago, IL. June 2-6, 2023
7. **Oral Presentation, 2023 Genitourinary Cancer Symposium (GU ASCO)**, TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). San Francisco, CA. February 15-17, 2023
8. **Oral Presentation, ESMO Congress 2021**, Proffered Paper session. Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study. Paris, France, September 16-21, 2021
9. **Oral Presentation, 2021 ASCO Annual Meeting**. Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). Chicago, IL. June 4-8, 2021
10. **Oral Presentation, 2020 Genitourinary Cancer Symposium (GU ASCO)**. Time to Second Progression (PFS2) in Patients from TITAN with Metastatic Castration-Sensitive Prostate Cancer by First Subsequent Therapy (Hormonal vs Taxane). San Francisco, CA. February 13-15, 2020
11. **Oral Presentation, 2019 ASCO Annual Meeting** – Balancing Disease Control and Quality of Life in Metastatic Renal Cell Carcinoma. Chicago, IL. May 31-June 4, 2019
12. **Oral Presentation, 2016 Genitourinary Cancer Symposium (GU ASCO)**. Novel Immunotherapeutic Approaches and Biomarkers in Renal Cell Carcinoma (RCC).

San Francisco, CA. January 7-9, 2016

**Invited Speaker:**

1. **Invited Speaker, Pittsburgh Annual Oncology Symposium: Experts & Evidence 2025.** Pittsburgh, PA, June 20, 2025
2. **Invited Speaker, National Alliance of State Prostate Cancer Coalitions (NASPCC) Webinar.** June 12, 2025
3. **Invited Speaker/Co-Chair, International Academic Exchange Conference on Prostate Cancer,** Fudan University Shanghai Cancer Center. Beijing, China, April 11, 2025
4. **Invited Speaker, Northside Hospital Cancer Institute 2025 Symposium: Personalizing Cancer Treatment in the Era of Genomics and Precision Oncology.** Atlanta, Georgia, March 29, 2025
5. **Invited Speaker, University of Utah Department of Internal Medicine Grand Rounds.** Salt Lake City, UT, December 19, 2024
6. **Invited Speaker, San Raffaele Urologic Oncology Retreat – Third edition 2024.** Milan, Italy, December 13, 2024
7. **Invited Speaker, All India Institute of Medical Sciences (AIIMS), New Delhi, Genitourinary Oncology Update 2024.** New Delhi, India, November 22, 2024
8. **Invited Speaker, Prostate Cancer Foundation (PCF) Webinar: Immunotherapy for Prostate Cancer: What's Now, What's Next?** November 18, 2024
9. **Invited Speaker (and Session Chair), Society of International Urology (SIU) 44<sup>th</sup> Annual Meeting.** New Delhi, India, October 23-26, 2024
10. **Invited Speaker, Keynote Speaker, SWOG Special GU symposium,** Keyways to improve accrual on clinical trials, 2024 SWOG Fall meeting. Chicago, IL, October 17, 2024
11. **Invited Speaker/ Keynote speaker, Second International Urology Summit (IUCS).** Portsmouth, United Kingdom, September 27, 2024
12. **Invited Speaker, World Conference on Genitourinary Cancers.** New York City, NY, August 2, 2024
13. **Invited Speaker, National Congress, Molecular Medicine from Laboratory to the Clinic** (sponsored by Institute of Molecular Medicine and Biomedical Research, Athens & ASCO). Athens, Greece, July 4-6, 2024
14. **Invited Speaker, Prostate Cancer Symposium with Research To Practice, 2024** ASCO Annual Meeting. Chicago, IL, June 1, 2024
15. **Invited Speaker, 2024 American Urology Association (AUA) Annual Meeting.** San Antonio, TX, May 5, 2024
16. **Invited Speaker, Canadian Urology Association (CUA) Webinar.** April 29, 2024
17. **Invited Speaker, University of Iowa Department of Internal Medicine Grand Rounds,** Iowa City, IA, April 11, 2024
18. **Panelist: DNA repair-focused working group; Prostate Cancer Foundation (PCF).** February 21, 2024
19. **Invited Speaker, Prostate Cancer Foundation (PCF) Clinician-Industry Roundtable,** Treatment of Metastatic Castration-Sensitive Prostate Cancer: When More is More. San Francisco, CA, January 26, 2024
20. **Faculty, Clinical Care Options (CCO) CME Symposium at ASCO GU 2024.** San Francisco, CA, January 25, 2024

21. **Invited Speaker, Medscape Live Virtual Program on Radiopharmaceutical in MCRPC.** December 15, 2023
22. **Invited Speaker, POET Program (Precision Oncology Experimental Therapeutics Program).** University of Calgary, November 30, 2023
23. **Invited Speaker, San Raffaele Urologic Oncology Retreat – Second edition 2023.** Milan, Italy, November 17, 2023
24. **Invited Speaker, Prostate Cancer Foundation, Clinical/Industry Roundtable on Metastatic Prostate Cancer, State of the Art for mHSPC.** Carlsbad, CA, October 26, 2023
25. **Invited Speaker, XXVI Argentine and International Congress of Clinical Oncology – 2023.** Plenary Session, Metastatic Prostate Cancer. La Rural – Buenos Aires Fairgrounds, Argentina, October 11, 2023
26. **Invited Speaker, First International Urology Cancer Summit (USCS).** Portsmouth, UK, September 29, 2023
27. **Invited Speaker, Society of Utah Medical Oncologists (SUMO) Clinical Oncology Conference.** Park City, UT, September 23, 2023
28. **Invited Speaker, Next Frontiers to Cure Cancer 2023,** A.C. Camargo Cancer Center Meeting. Brasilia, Brazil, September 15, 2023
29. **Invited Expert/Panelist, MCI India, ASCO Direct Highlights.** Chennai, India, September 10, 2023
30. **Invited Speaker and Faculty, 2023 Thought Leaders of the Future Faculty, Prostate Cancer Foundation (PCF).** Los Angeles, CA, August 12, 2023
31. **Invited Speaker, TotalCME, HO-3095, Program 1025 - Prostate Cancer: Focusing Androgen Receptor Inhibitors on High-Risk Localized & Locally Advanced Disease.** July 19, 2023
32. **Invited Speaker, Faculty Research To Practice (RTP), PARP Prostate Cancer Think Tank.** July 14, 2023
33. **Invited Speaker, China Primary Health Care Foundation.** June 27, 2023
34. **Invited Speaker, GoToWebinar - National Alliance of State Prostate Cancer Coalitions Webinar Series.** June 15, 2023
35. **Invited Speaker, OncLive State of the Science Summit: Prostate/RCC Cancers.** Cleveland, OH, June 14, 2023
36. **Invited Speaker, AXIS Medical Education, ReachMD Live Broadcast.** June 12, 2023
37. **Invited Speaker, EPG Health, ASCO Congress Highlights Interview – mCRPC.** June 12, 2023
38. **Invited Speaker, ASCO Prostate PARP Satellite Symposium, Physicians Education Resource (PER).** June 4, 2023
39. **Invited Speaker and Session Chair, Prioritizing and Sequencing Therapy for Advanced Prostate Cancer, 2023 ASCO Annual Meeting.** Chicago, IL, June 1-5, 2023
40. **Invited Speaker, China Primary Health Care Foundation, An online Medical Education of Prostate Cancer in academic progress and exchanges between China and Global from China.** May 15, 2023
41. **Invited Speaker, MedPRO, A Master Lecture Series – How the Master’s Treat Cancer.** Seattle, Washington, May 6, 2023
42. **Invited Speaker, Fifteenth Annual Research to Practice (RTP) Symposium Series Held During the Annual ONS Congress.** San Antonio, TX, April 29, 2023
43. **Invited Speaker, The ASCO Post Roundtable on Prostate Cancer.** March 31, 2023

44. **Invited Speaker, OncLive US PROST8 Conference.** San Francisco, CA, February 18-19, 2023
45. **Program Chair, Clinical Education Alliance (CEA), CCO Symposium at ASCO GUCS 2023.** San Francisco, CA, February 15, 2023
46. **Invited Speaker, CONTACT-02 (XL184-315) Japan Investigator Meeting.** February 4, 2023
47. **Invited Speaker, Baptist Health, Inaugural Miami Cancer Institute Precision Oncology Symposium.** Miami, FL, February 4, 2023
48. **Invited Speaker, Desai Sethi Urology Institute, Urology on the Beach 2023 Conference.** Miami Beach, FL, January 14, 2023
49. **Invited Speaker, Grand Rounds, Georgia Cancer Center.** Augusta University, November 18, 2022
50. **Invited Speaker, Targeted Oncology Prostate Cancer Case-Based Roundtable.** November 16, 2022
51. **Invited Speaker, GU Connect (COR2ED), Expert Knowledge Share.** November 14, 2022
52. **Invited Speaker, DAVA's 5<sup>th</sup> Annual Global Summit on Genitourinary Malignancies.** Banff, Canada, November 10-13, 2022
53. **Invited Speaker, 29<sup>th</sup> Annual Prostate Cancer Foundation (PCF) Retreat.** Carlsbad, CA, October 5, 2022
54. **Invited Speaker, 9<sup>th</sup> Annual Congress of the European Society for Translational Medicine on Immunotherapeutics – From Biology to Patient Care (EUSTM-2022) (virtual) Session.** October 3-5, 2022
55. **Invited Speaker, Uromigos Live & Unplugged, Prostate Cancer Panel Discussion.** Nashville, TN, September 30-October 1, 2022
56. **Invited Speaker, GU Connect (COR2ED), Meeting Summary Prostate Cancer Highlights from ESMO 2022.** September 14, 2022
57. **Invited Speaker, Talzena Prostate Launch Meeting.** Paris, France, September 9, 2022
58. **Invited Speaker, Targeted Oncology: Case-Based Roundtable in Prostate Cancer.** September 1, 2022
59. **Invited Speaker, Contact-02 Buenos Aires Investigator Meeting.** Buenos Aires, ARG, August 26, 2022
60. **Invited Panelist, American Oncology Network (AON) Webinar.** August 6, 2022
61. **Invited Speaker, Catamount Medical Education, Treatment Paradigms in Advanced Prostate Cancer: Exploring the Role of PARP Inhibitor Combinations.** July 8, 2022
62. **Invited Speaker, Molecular Medicine from Laboratory to Practice.** Athens, Greece, June 30, 2022
63. **Invited Speaker, UroToday Post-ASCO 2022 Discussion.** June 24, 2022
64. **Invited Speaker, ASCO-Argentine Association of Clinical Oncology (AAOC) Virtual Joint Session.** June 24, 2022
65. **Invited Speaker, 32<sup>nd</sup> International Prostate Cancer Update (IPCU 32).** Snowbird, UT, March 6-9, 2022
66. **Invited Speaker, Brazilian Information Oncology, Best of ASCO GU 22, Brazil, (ASCO GU).** March 12, 2022
67. **Invited Speaker, Research to Practice (RTP) satellite CME Symposium, 2022 ASCO GU Meeting.** San Francisco, CA, February 17, 2022

68. **Invited Speaker**, Clinical Hematology & Oncology: 2022, **Scripps MD Anderson Cancer Center**. San Diego, CA, February 13, 2022
69. **Invited Speaker**, Committee of Genitourinary (GU) Cancers, **Beijing Anti-Cancer Association (BACA)**. Beijing, China, January 6, 2022
70. **Invited Speaker**, International Oncology Symposium, **Hospital Porto Dias**. Brazil, November 13, 2021
71. **Invited Speaker**, **1st International Genitourinary Cancer Conference (IGCC)**. Jeddah, Saudi Arabia, November 5-6, 2021
72. **Invited Speaker**, 12<sup>th</sup> Muscat International Oncology Online Conference, **National Oncology Center**. Royal Hospital, October 17-18, 2021
73. **Invited Speaker**, **V GU Review – LACOG-GU Symposium**. October 14, 2021
74. **Session Chair and Invited Speaker**, Precision Oncology Summit, **Binaytara Foundation**. Salt Lake City, UT, October 3, 2021
75. **Invited Speaker**, Advancement in Treatment for mCSPC, **1st Annual Advances in Men’s Health**. Whitefish, MT, August 25, 2021
76. **Invited Speaker**, GU Malignancies, **ASCO Direct Highlight: 2021 Official Annual Meeting Review**. Seattle, WA, July 25, 2021
77. **Invited Speaker**, Genitourinary Cancer – Prostate Update, **Genitourinary Cancer Session at the Virtual ASCO Direct Denver program**. Denver, CO, July 18, 2021
78. **Invited Speaker**, Recent Advancement in the Treatment of Metastatic Castration Sensitive Prostate Cancer (mCSPC) and Real World Utilization of Guideline Based Therapy in mCSPC: Update from the 2021 ASCO Annual Meeting, **31st Annual International Prostate Cancer Update (IPCU)**. Snowbird, UT, July 16, 2021
79. **Invited Speaker**, Highlights in Genitourinary Cancers, **PER’s ASCO Direct Highlight**. Las Vegas, Nevada, June 26, 2021
80. **Invited Speaker**, Targeting DNA damage Response Pathways in Prostate Cancer, **Hematology-Oncology Fellows Conference & Grand Rounds**. Mt. Sinai, NYC, May 13, 2021
81. **Invited Speaker**, Metastatic Castration-Sensitive Prostate Cancer: Recent Strides in Drug and Biomarker Development, **Grand Rounds**, Taussig Cancer Center, Cleveland Clinic. April 9, 2021
82. **Invited Speaker**, Metastatic Castration Sensitive Prostate Cancer: Recent Strides in Drug and Biomarker Development, **Hematology-Oncology, Grand Rounds**, Stephenson Cancer Center. **University of Oklahoma**, March 19, 2021
83. **Invited Speaker**, Metastatic Castration Sensitive Prostate Cancer, Institutional Perspective on Prostate Cancer, University of Washington, **OnLive State of Science Summit**. November 24, 2020
84. **Invited Speaker**, Emerging Role of PARP Inhibitors in Prostate Cancer, **Prime Oncology CME**, Prime Education LLC, Fort Lauderdale, FL (Virtual), October 31, 2020
85. **Invited Speaker**, The Universe of Castration Sensitive Prostate Cancer, **UroTarget 2020, Argentina Oncology Association (AAOC)**. October 31, 2020
86. **Invited Speaker**, Updates in the Management of Advanced Prostate Cancer and Personalizing Therapy, **Grand Rounds**, Fred Hutchinson Cancer Research Center. **University of Washington**, October 5, 2020

87. **Invited Speaker**, Updates in Prostate Cancer, **ASCO Direct UAE 2020 Webinar**, Genitourinary Oncology, **Emirates Oncology Society**. Abu Dhabi, UAE, October 3, 2020
88. **Invited Speaker**, Opinions in Bladder Cancer, **Curio Science**. Denver CO (Virtual), September 30, 2020
89. **Invited Speaker**, Systemic Therapy of Low Volume Metastatic Castration Sensitive Prostate Cancer, **ONCO 2020, Society of Urology of Columbian/Ecuador/Peru**. September 25, 2020
90. **Invited Speaker, National Congress**, Molecular Medicine from Laboratory to Practice. Athens, Greece, March 12, 2020
91. **Invited Speaker, Tata Memorial Cancer Centre, 18<sup>th</sup> Annual Conference on Evidence Based Management of Cancers in India**, Uro Oncology- Decade of Transformation. Mumbai, India, February 28-March 1, 2020
92. **Invited Speaker, OnConnect (9<sup>th</sup> PCF) meeting**. Sao Paulo, Brazil, August 16-17, 2019
93. **Invited Speaker, Oncology Grand Rounds. Saint Vincent’s Medical Center**, Immunotherapeutic Strategies for Advanced Renal Cell Carcinoma. Bridgeport, CT, August 30, 2019
94. **Invited Speaker**, Treatment and Biomarkers in Metastatic Prostate Cancer, Grand Rounds, Department of Internal Medicine. **University of Utah**, July 18, 2019.
95. **Invited Speaker**, Science Friday/ SciFri (with Ira Flatow), New York Public Radio. Making Cancer Drugs Available For A Wider Pool Of Patients. 06/07/2019. Web Link: <https://www.sciencefriday.com/segments/making-cancer-drugs-available-for-a-wider-pool-of-patients/>
96. **Invited Speaker and Panelist, Juravinski and Walker Cancer Centres Uro-oncology Forum 2019**. Niagara-On-The-Lake, ON, Canada, March 2, 2019
97. **Invited Speaker, Canadian Urology Association. Grand Round** talks at McGill University Health Centre (MUHC), Centre hospitalier de l’Universite de Montreal (CHUM), Jewish General Hospital, London Regional Cancer Centre, and Princess Margaret Cancer Centre (UHN), Feb 27-March 1, 2019
98. **Invited Speaker and Chair, OncLive State of Science Summit**, Motif Seattle. Seattle, WA, December 13, 2018
99. **Invited Speaker and Session Moderator, 17<sup>th</sup> International Kidney Cancer Symposium**, Kidney Cancer Association. Miami, FL, November 2-3, 2018
100. **Invited Speaker, Cardinal Health Oncology Summit**. Orlando, FL, November 11, 2018
101. **Invited Speaker and Session Chair, 2018 American Society of Clinical Oncology (ASCO 2018) annual meeting** – Treatment of Metastatic Castration Naïve Prostate Cancer, Prostate Cancer Tumor Board, Education Session, Chicago, IL, June 4, 2018
102. **Invited Speaker, 2018 ASCO Pre-Annual Meeting Seminar**– Cancer Immunotherapy Today: Maximizing Patient Outcomes. Immunotherapy Update in Genitourinary Oncology. Chicago, IL, June 1, 2018
103. **Invited Speaker and Chair, 2018 Huntsman Cancer Institute Genitourinary Oncology Symposium**. Salt Lake City, UT, May 25, 2018
104. **Invited Speaker and Chair, OncLive State of Science Summit**, Little America Hotel. Salt Lake City, UT, May 24, 2018

105. **Invited Speaker, Targeted Oncology Conference.** Napa, CA, March 16, 2018
106. **Invited Speaker, American Society of Clinical Oncology (ASCO) University Faculty Speaker (webcast),** February 2018: Treatment of Castration Sensitive Metastatic Prostate Cancer
107. **Invited Speaker, Grand Rounds, Division of Nephrology and Hypertension.** University of California, Irvine, November 27, 2017
108. **Invited Speaker, 8<sup>th</sup> SOGUG (Spanish Genitourinary Oncology Group) Science Meeting.** Madrid, Spain, November 17, 2017
109. **Invited Speaker, Cardinal Health Science Summit.** Phoenix, AZ, November 11, 2017
110. **Invited Speaker and Panel Member, Medical Crossfire, 2017 Chemotherapy Foundation Symposium (Greenspan Meeting).** New York City, NY, November 10, 2017
111. **Invited Speaker and Panel Member, City of Hope Cancer Center Grand Rounds: Update on Genitourinary Cancers.** Duarte, CA, November 7, 2017.
112. **Invited Speaker and Panel Member, Onclive State of Science Summit.** Los Angeles, CA, November 6, 2017
113. **Invited Speaker and Panel Member, 16<sup>th</sup> International Kidney Cancer Symposium.** Miami, FL, November 3-4, 2017
114. **Invited Speaker, 2017 American Society of Clinical Oncology (ASCO 2017) annual meeting- Education Session.** Chicago, IL, June 3<sup>rd</sup>, 2017
115. **Invited Speaker and panel member, 2017 American Endocrine Society (ENDO 2017) annual meeting.** Orlando, FL, April 2<sup>nd</sup>, 2017
116. **Invited Speaker and Panel Member, University of Utah School of Medicine Seminar: “How to Succeed in Research.”** February 13<sup>th</sup>, 2017
117. **Invited Speaker, 17th Annual Meeting of the Society of Urologic Oncology (SUO).** San Antonio, TX, December 1, 2016
118. **Invited Speaker, 15<sup>th</sup> International Kidney Cancer Symposium (IKCS meeting).** Miami, FL, November 4, 2016
119. **Invited Speaker, Cancer Biology Seminar Series, University of California Davis Comprehensive Cancer Center.** Sacramento, CA, August 18, 2016
120. **Invited Speaker, Society of Urologic Oncology (SUO) meeting, 16<sup>th</sup> Annual meeting.** Washington DC, December 4, 2015
121. **Invited Speaker, 14<sup>th</sup> International Kidney Cancer Symposium (IKCS meeting).** Miami, FL, November 6, 2015
122. **Invited Speaker, Fall Utah Urologic Summit.** University of Utah, Park City, Utah, September 26, 2015
123. **Invited Speaker, Cancer Center Grand Rounds, Cleveland Clinic Taussig Cancer Institute.** Cleveland, OH, May 8, 2015
124. **Invited Speaker, XXI Rio Journey of Urology, Brazilian Society of Urology.** Rio de Janeiro, Brazil, November 19, 2014
125. **Invited Speaker, Fall Utah Urologic Summit,** University of Utah. Park City, Utah, September 28, 2014
126. **Invited Speaker, Scripps Clinic 11<sup>th</sup> Annual Oncology Update.** Las Vegas, NV, August 9, 2014

127. **Invited Speaker**, Cancer Center Grand Rounds, **City of Hope** Comprehensive Cancer Center. Duarte, CA, September 24, 2013
128. **Invited Speaker**, Grand Rounds, Department of Internal Medicine, **University of Utah**. July 30, 2009
129. **Invited Speaker**, **MD Anderson Cancer Center** “9th Annual Oncology Update: Advances and Controversies”. Park City, Utah, January 18, 2008
130. **Invited Speaker**, **National Institute of Health**-National Institute of Aging (United States, NIH-NIA), Anemia in Aging Workshop, Bethesda, MD. September 22, 2008
131. **Invited Speaker**, **Utah Urologic Society** Annual Meeting, Salt Lake City, Utah, February 2008
132. **Invited Speaker**, **Grand Rounds**, Division of Geriatrics and Center of Aging. **University of Utah**, October 14, 2008

### **Publications (PubMed ID/ PMID number) (Total: 536)**

#### **A. Original Research Articles (Total: 320)**

1. **Agarwal N**, Handa R, Acharya SK, Wali JP, Dinda AK, Aggarwal P. A study of autoimmune markers in Hepatitis C infection. **Indian Journal of Medical Research. 2001**. PMID: 11968950.
2. **Agarwal N**, Kutlar F, Mojica-Henshaw MP, Ou CN, Gaikwad A, Reading S, Bailey L, Kutlar A, Prchal JT. Missense Mutation of the Last Nucleotide of Exon 1 (G->C) of  $\beta$  globin Gene not only leads to Undetectable Mutant Peptide and Transcript but also interferes with the Expression of Wild Allele. **Haematologica. 2007**. PMID: 18056002.
3. **Agarwal N**, Mojica-Henshaw MP, Simmons ED, Hussey D, Ou CN, Prchal JT. Familial Polycythemia Caused by a Novel Mutation in the Beta Globin Gene: Essential Role of P50 in Evaluation of Familial Polycythemia. **International Journal of Medical Sciences. 2007**. PMID: 17952198.
4. Anderson M, Hartz A, Nordin T, Rosenbaum M, Noyes R, James P, Ely J, **Agarwal N**, Anderson S. Strategies Used by Community Clinicians to Manage Patients with Medically Unexplained Symptoms. **Family Medicine. 2008**. PMID: 18247177.
5. Swierczek S\*, **Agarwal N\***, Nussenzveig R\*, Rothstein G, Wilson A, Artz A, Prchal J (\*equal contribution). Hematopoiesis is Not Clonal in Healthy Elderly Females? **Blood. 2008**. PMID: 18641369.
6. Montejo M, Bentz B, Hunt J, Buchman L, **Agarwal N**, Hitchcock Y. IMRT with Simultaneous Integrated Boost and Concurrent Chemotherapy for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. **International Journal of Radiation Oncology, Biology, Physics. 2011**. PMID: 21167654.
7. Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding, **Agarwal N**, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy of advanced renal cell carcinoma. **Journal of Clinical Oncology. 2012**. PMID: 22430274.
8. Swierczek SI, Piterkova L, Jelinek J, **Agarwal N**, Hammoud S, Wilson A, Hickman K, Parker CJ, Cairns B, Prchal JT. Methylation of AR Locus Does Not Always Reflect X Chromosome Inactivation State. **Blood. 2012**. PMID: 22286197.

9. Harshman LC, Xie W, Bjarnason G, Knox J, MacKenzie M, Wood L, Srinivas S, Vaishampayan U, Tan MH, Rha SY, Donskov FN, **Agarwal N**, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK. Conditional survival of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor (VEGF) targeted therapy: results from the International Metastatic RCC Database Consortium. **Lancet Oncology**. 2012. PMID: 22877847.
10. Fury MG, Sherman E, Lisa D, **Agarwal N**, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan K, Jafri N, Korte S, Lipson B, Yunis F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG. A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m<sup>2</sup> for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC). **Journal of National Comprehensive Cancer Network (JNCCN)**. 2012. PMID: 23138167.
11. Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, Mackenzie M, Knox JJ, **Agarwal N**, Al-Harbi H, Kollmannsberger C, Tan MH, Rha SY, Donskov FN, North S, Choueiri TK, Heng DY; For the International mRCC Database Consortium. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF- targeted therapy in metastatic renal cell carcinoma patients. **Targeted Oncology**. 2013. PMID: 23300029.
12. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason G, Vaishampayan U, MacKenzie MJ, Wood LA, Donskov F, Tan MH, Rha SY, **Agarwal N**, Kollmannsberger CK, Rini BI, and Choueiri TK. External validation of the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model and comparison to other models in the era of targeted therapy. **Lancet Oncology**. 2013. PMID: 23312463.
13. Maughan B\*, **Agarwal N\***, Hussain SA, Boucher KM, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G (\***equal contribution**). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. **Clinical Genitourinary Cancer**. 2013. PMID: 23332638.
14. Campo RA, O'Connor K, Light KC, Nakamura Y, Lipschitz D, LaStayo PC, Pappas L, Boucher K, Irwin MR, **Agarwal N**, & Kinney AY. Feasibility and Acceptability of a Tai Chi Chih Randomized Controlled Trial in Senior Female Cancer Survivors. **Integrative Cancer Therapies**. 2013. PMID: 23620504.
15. Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, **Agarwal N**, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, and Heng DY. Metastatic non clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium (IMDC) Criteria. **Cancer**. 2013. PMID: 23696129.
16. Pond GR, Bellmunt J, Fougerey R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Lorenzo GD, Salhi Y, Galsky MD, **Agarwal N**, Necchi A, Sonpavde G. Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design. **Clinical Genitourinary Cancer**. 2013. PMID: 23800847.
17. Birmingham WC, **Agarwal N**, Kohlmann W, Aspinwall LG, Wang M, Bishoff J, Dechet C, Kinney AY. Patient and provider attitudes toward genomic testing for prostate cancer

- susceptibility: a mixed method study. **BMC Health Services Research. 2013.** PMID: 23870420.
18. Quinn DI, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Carducci M, Monk PJ, Twardowski PW, Veldhuizen PJ, **Agarwal N**, Higano CS, Vogelzang N, Thompson IM. A Randomised Trial of Docetaxel and Atrasentan compared to Docetaxel and Placebo for Men with Advanced Castration Resistant Prostate Cancer: SWOG S0421. **Lancet Oncology. 2013.** PMID: 23871417.
  19. Nelson Q, **Agarwal N**, Stephenson R, Cannon Albright L. A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer. **Frontiers in Genetics. 2013.** PMID: 23970893.
  20. Light KC, **Agarwal N**, Jacob E, White AT, Kinney AY, Van Haitsma T, Aizad H, Hughen RW, Bateman L, Light AR. Altered Leukocyte Gene Expression Profiles Associated with Fatigue in Patients with Prostate Cancer versus Chronic Fatigue Syndrome. **Psychoneuroendocrinology. 2013.** PMID: 24054763.
  21. Swierczek S, Agarwal A, Naidoo K, Lorenzo FR, Whisenant J, **Agarwal N**, Coetzer TL, Prchal JT. Novel Exon 2 alpha Spectrin Mutation and Intragenic Crossover: Three Morphological Phenotypes Associated with Four Distinct alpha Spectrin Defects. **Haematologica. 2013.** PMID: 24077844.
  22. Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, **Agarwal N**, Tan MH, Bamis A, Kollmannsberger CK, North SA, Rini BI, Heng DY. Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma (RCC) in the Era of Targeted Therapy. **European Urology. 2014.** PMID: 23916693.
  23. Alwan LM, Grossmann K, Sageser D, Van Atta J, **Agarwal N**, Gilreath JA. Comparison of Acute Toxicity and Mortality after Two Different Dosing Regimens of High-Dose Interleukin-2 for Patients with Metastatic Melanoma. **Targeted Oncology. 2014.** PMID: 23609056.
  24. Bendell JC, Gordon MS, Hurwitz HI, Jones S, Mendelson DS, Blobe GC, **Agarwal N**, Condon CH, Wilson D, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S. Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of Dalantercept (ACE-041), a Soluble Activin Receptor- Like Kinase-1 Ligand Trap, in Patients with Advanced Solid Tumors. **Clinical Cancer Research. 2014.** PMID: 24173543.
  25. Campo RA, **Agarwal N**, LaStayo P, O'Connor K, Gardner J, Smith S, Pappas L, Boucher K, Light KC, & Kinney AY. Effects of a 12-week randomized Qigong intervention on senior prostate cancer survivors' levels of fatigue and distress. **Journal of Cancer Survivorship. 2014.** PMID: 24170679.
  26. Schutz F, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, **Agarwal N**, Pal SK, Srinivas S, Kollmannsberger CK, North SA, Wood LA, Vaishampayan U, Tan MF, MacKenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, and Choueiri TK. The impact of low serum sodium on treatment outcome to targeted therapy in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. **European Urology. 2014.** PMID: 24184025.
  27. Gartrell B, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD, **Agarwal N**. Pulmonary complications with the use of mTOR inhibitors for cancer therapy. **Targeted Oncology. 2014.** PMID: 23852656.

28. Sivendran S, **Agarwal N**, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD. Metabolic complications with the use of mTOR inhibitors for cancer therapy. **Cancer Treatment Reviews**. 2014. PMID: 23684373.
29. **Agarwal N**, Bellmunt J, Maughan B, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko Y, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Six-month progression-free survival as an endpoint to evaluate second line therapy for advanced urothelial carcinoma. **Clinical Genitourinary Cancer**. 2014. PMID: 24220220.
30. Pond GR\*, **Agarwal N \***, Bellmunt J\*, Choueiri TK, Qu AQ, Fougeray R, Niegisch G, Galsky MD, Wong YN, Stadler WM, Sridhar SS, Vogelzang NJ, Sternberg CN, Sonpavde G (**\*equal contribution**). The impact of baseline prognostic factors on primary endpoints employed in phase II trials of second-line therapy for advanced urothelial carcinoma. **BJU International**. 2014. PMID: 24219029.
31. Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie M, Vaishampayan UN, Tan MH, Rha SY, Donskov F, **Agarwal N**, Kollmannsberger C, North S, Wood LA. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. **Annals of Oncology**. 2014. PMID: 24356626.
32. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski PW, Van Veldhuizen PJ, **Agarwal N**, Carducci M, Monk III PJ, Datar RH, Garzotto MG, Mack PC, Lara Jr. P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a Phase 3 trial of docetaxel with or without atrasentan for metastatic castration resistant prostate cancer. **Journal of Clinical Oncology**. 2014. PMID: 24616308.
33. Albright F, Stephenson RA, **Agarwal N**, Teerlink CC, Lowrance WT, Farnham JM, Cannon-Albright LA. Prostate cancer risk prediction based on complete prostate cancer family history. **The Prostate**. 2015. PMID: 25408531.
34. Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono Johann, Melo Cruz F, Fountzilas G, Ulys A, Carcano F, **Agarwal N**, Agus D, Bellmunt J, Petrylak D, Lee SY, Webb I, Tejura B, Borgstein N, Dreicer R. A phase 3, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during the following docetaxel-based therapy: ELM-PC 5. **Journal of Clinical Oncology**. 2015. PMID: 25624429.
35. Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators (**Agarwal N**). Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELMPC 4): a double-blind, multicenter, phase 3, randomized, placebo-controlled trial. **Lancet Oncology**. 2015. PMID: 25701170.
36. Yu E, Cheng H, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan U, **Agarwal N**, Heath E, Pal SK, Rehman H, Leiter A, Batten J, Montgomery B, Galsky M, Antonarakis E, Chi K. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. **Prostate Cancer and Prostatic Diseases**. 2015. PMID: 25600186.

37. Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, Mackenzie MJ, Wood L, Vaishampayan UN, **Agarwal N**, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, Bamias A, Heng DY. First-, second-, third-line therapy for mRCC: benchmarks for the trial design from the IMDC. **British Journal of Cancer**. 2014. PMID: 24691425.
38. Hussain M, Grivas P, **Agarwal N**, Levine E, Mcvicar G, Puzanov I, Siefker-Radtke A, Srinivas S, Twardowski P, Eisenberger M, Quinn D, Yu E, Vaishampayan U. Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC). **Cancer**. 2014. PMID: 24802654.
39. Cannon-Albright LA, Farnham J, Bailey M, Albright FS, Teerlink CC, **Agarwal N**, Stephenson R, Thomas A. Identification of specific Y chromosomes associated with increased risk for prostate cancer. **The Prostate**. 2014. PMID: 24796687.
40. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, **Agarwal N**, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry BM, Gagnier P, Liu D, Gerritsen WR. Ipilimumab versus placebo for patients with post-docetaxel metastatic castration-resistant prostate cancer (CA184-043): a multicenter, randomized, double-blind phase 3 trial. **Lancet Oncology**. 2014. PMID: 24831977.
41. Dahal A, Bellows BK, Sonpavde G, Tantravahi SK, Choueiri TK, Galsky MD, **Agarwal N**. Incidence of severe nephrotoxicity with cisplatin, based on renal function eligibility criteria: Indirect comparison meta-analysis. **American Journal of Clinical Oncology**. 2014. PMID: 24824144.
42. Heng D, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, **Agarwal N**, Vaisampayan UN, Rha SY, Kim JJ, Choueiri TK. Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). **European Urology**. 2014. PMID: 24931622.
43. **Agarwal N**, Apolo AB, Tsao CK, Lee KM, Godbold JH, Soto R, Poole A, Gimpel-Tetra K, Lowe N, Oh WK, Galsky MD. Phase Ib/II Trial of Gemcitabine, Cisplatin, plus Lenalidomide as First Line Therapy in Patients with Metastatic Urothelial Carcinoma. **The Oncologist**. 2014. PMID: 25052451.
44. Lam ET, Wong MKK, **Agarwal N**, Redman BG, Logan T, Flaig TW, Monk III JP, Jarkowski A, Sendilnathan A, Bolden M, Kuzel T, Olencki T. Safety and efficacy of sequencing high-dose interleukin 2 (IL2) after tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma. **Journal of Immunotherapy**. 2014. PMID: 25075565.
45. Campo RA, Light KC, O'Connor K, Nakamura Y, Lipschitz D, LaStayo PC, Pappas L, Boucher K, Irwin MR, Hill HR, Martins TB, **Agarwal N** & Kinney AY. Blood Pressure, Cortisol, and Inflammatory Cytokines in Senior Female Cancer Survivors Enrolled in a Tai Chi Chih Trial. **Journal of Cancer Survivorship**. 2014. PMID: 25164513.
46. Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, **Agarwal N**, Carducci MA, Monk JP 3rd, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Vogelzang NJ, Thompson IM Jr, Cote RJ, Quinn DI. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase

- III metastatic castration resistant prostate cancer trial. **International Journal of Cancer**. **2014**. PMID: 25219358.
47. Necchi A, Pond G, Giannatempo P, Di Lorenzo G, Eigl B, Locke J, Pal SK, **Agarwal N**, Poole A, Vaishampayan UN, Niegisch G, Hussain SA, Singh P, Bellmunt J, Sonpavde G. Cisplatin-based first-line therapy for advanced urothelial carcinoma following previous perioperative cisplatin-based therapy. **Clinical Genitourinary Cancer**. **2014**. PMID: 25450035.
  48. Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, **Agarwal N**, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI. Outcome of Patients with Metastatic Sarcomatoid Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. **Clinical Genitourinary Cancer**. **2014**. PMID: 25450036.
  49. Fay AP, Wanling LX, Lee JL, Harshman LC, Bjarnason GA, Knox JJ, Ernst S, Wood L, Vaishampayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, **Agarwal N**, Kollmannsberger CK, North SA, Rini BI, Choueiri TK, Heng D. Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated with Targeted Therapies: Results From the International mRCC Database Consortium. **Clinical Genitourinary Cancer**. **2014**. PMID: 25458371.
  50. Pal SK, He M, Wilson T, Liu X, Zhang K, Carmichael C, Torres A, Hernandez S, Lau C, **Agarwal N**, Kawachi M, Yen Y, Jones JO. Detection and Phenotyping of Circulating Tumor Cells in High-Risk Localized Prostate Cancer. **Clinical Genitourinary Cancer**. **2014**. PMID: 25450039.
  51. Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Patel SB, Wells CE, Stenhjem D, **Agarwal N**. Correlation of severity of hypothyroidism and survival outcomes in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. **Clinical Genitourinary Cancer**. **2014**. PMID: 25497584.
  52. Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, **Agarwal N**, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line therapy: a population based study. **Lancet Oncology**. **2015**. PMID: 25681967.
  53. Tantravahi SK, Albertson D, Agarwal AM, Ravulapati S, Poole A, Patel SB, Hawatmeh JS, Straubhar AM, Liu T, Stenhjem DD, **Agarwal N**. Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. **Journal of Oncology**. **2015**. PMID: 25688268.
  54. Yu EY, Li H, Higano CS, **Agarwal N**, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM Jr. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. **Journal of Clinical Oncology**. **2015**. PMID: 25847934.
  55. Diamond JR, Wu B, **Agarwal N**, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S. Pharmacokinetic drug-drug interaction

- study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. **Investigational New Drugs.** 2015. PMID: 25895965.
56. Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, **Agarwal N**, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle invasive bladder cancer. **Cancer.** 2015. PMID: 25872978.
  57. Horn KP, Yap JT, **Agarwal N**, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. **Cancer Imaging.** 2015. PMID: 26335224.
  58. Werner TL, Wade ML, **Agarwal N**, Boucher K, Patel J, Luebke A, Sharma S. A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR- $\beta$ , and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. **Investigational New Drugs.** 2015. PMID: 26365907.
  59. Pal SK, Vuong W, Zhang W, Deng J, Liu X, Carmichael C, Ruel N, Pinnamaneni M, Twardowski P, Lau C, Yu H, Figlin RA, **Agarwal N**, Jones JO. Clinical and translational assessment of VEGFR1 as a mediator of the pre-metastatic niche in high-risk localized prostate cancer. **Molecular Cancer Therapeutics.** 2015. PMID: 26450920.
  60. **Agarwal N**, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma S. A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. **Cancer Chemotherapy and Pharmacology.** 2015. PMID: 26719074.
  61. Munster PN, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner T, Dees EC, Bergsland EK, **Agarwal N**, Kleha JF, Durante M, Adams LM, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-kinase inhibitor, in Patients with Advanced Solid Tumor Malignancies. **Clinical Cancer Research.** 2015. PMID: 26603258.
  62. Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Di Lorenzo G, Vaishampayan UN, North SA, **Agarwal N**, Hussain SA, Pal S, Eigl BJ. Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated with Perioperative Cisplatin. **Clinical Genitourinary Cancer.** 2015. PMID: 26589729.
  63. Patel SB, Stenhjem DD, Gill DM, Tantravahi SK, Agarwal AM, Hsu J, Vuong W, Pal SK, **Agarwal N**. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. **Clinical Genitourinary Cancer.** 2015. PMID: 26781820.
  64. Penson DF, Armstrong AJ, Concepcion R, **Agarwal N**, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoschik A, Phung, Higano CS. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. **Journal of Clinical Oncology.** 2016. PMID: 26811535.

65. Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, De Velasco G, Tyburczy M, Hamieh L, Albiges L, **Agarwal N**, Ho TH, Song J, Pignon JC, Barrios PM, Michaelson MD, Van Allen EM, Krajewski KM, Porta C, Pal SK, Bellmunt J, McDermott DF, Heng DY, Gray KP, Signoretti S. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic Renal Cell Carcinoma. **Clinical Cancer Research**. 2016. PMID: 26831717.
66. **Agarwal N**, Machiels JP, Suarez C, Lewis N, Higgins M, Wisinski K, Awada A, Maur M, Stein M, Hwang A, Mosher R, Wasserman E, Wu G, Zhang H, Zieba R, Elmeliegy M. Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer. **The Oncologist**. 2016. PMID: 27091421
67. **Agarwal N**, Alex AB, Farnham JM, Patel S, Gill D, Buckley TH, Stephenson RA, Cannon-Albright L. Inherited variants in SULT1E1 and response to abiraterone acetate in men with metastatic castration refractory prostate cancer (mCRPC). **Journal of Urology**. 2016. PMID: 27150425.
68. Stenhjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Gill D, Straubhar AM, Agarwal AM, Grossmann KF, Samlowski WE, Redman B, **Agarwal N\***, Alva A\* (\*co-corresponding author). Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. **Cancer Immunology Immunotherapy**. 2016. PMID: 27277816.
69. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DY, Schmidinger M, **Agarwal N**, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ, METEOR Investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomized, open-label, phase 3 trial. **Lancet Oncology**. 2016. PMID: 27279544.
70. Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, **Agarwal N**, Khvorostenko D, Lyulko O, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bögemann M, Hutson T, Milecki P, Chowdhury S, Gallardo E, Schwartzmann G, Pouget JC, Baton F, Nederman T, Tuvesson H, Carducci M. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration Resistant Prostate Cancer. **Journal of Clinical Oncology**. 2016. PMID: 27298414.
71. Wells JC, Stukalin I, Norton C, Srinivas S, Lee JL, Donskov F, Bjarnason GA, Yamamoto H, Beuselinck B, Rini BI, Knox JJ, **Agarwal N**, Ernst DS, Pal SK, Wood LA, Bamias A, Alva AS, Kanesvaran R, Choueiri TK, Heng DY. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. **European Urology**. 2016. PMID: 27318422.
72. Parker SJ, Pond GR, **Agarwal N**, Alex A, Heilbrun ME, Sonpavde G. Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer. **Clinical Genitourinary Cancer**. 2016. PMID: 27338517.
73. Albright FS, Stephenson RA, **Agarwal N**, Cannon-Albright LA. Relative Risks for Lethal Prostate Cancer Based on Complete Family History of Prostate Cancer Death. **Prostate**. 2016. PMID: 27527734.

74. Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, **Agarwal N**, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DY, Choueiri TK. Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. **Journal of Clinical Oncology**. **2016**. PMID: 27601543.
75. Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, **Agarwal N**. Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. **Ecancermedicalscience**. **2016**. PMID: 27729941.
76. Alva A, Daniels GA, Wong MK, Kaufman HL, Morse Ma, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, **Agarwal N**, Lowder JN, Hua H, Aung S, Dutcher JP. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. **Cancer Immunology, Immunotherapy**. **2016**. PMID: 27714434.
77. Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg Cn, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, **Agarwal N**, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L, RISC Investigators. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). **European Urology**. **2016**. PMID: 27726966.
78. Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S Batten J, Reddy G, Bhat G, Sharma S, **Agarwal N**. A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. **Cancer Chemotherapy and Pharmacology**. **2016**. PMID: 27744565.
79. Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, **Agarwal N**, Srinivas S, Yuasa T, Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knox JJ, Pantuck A, Saleem S, Alva A, Rini BI, Lee JL, Choueiri TK, Heng DY. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. **European Urology**. **2016**. PMID: 27771126.
80. Clark JI, Wong MK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, **Agarwal N**, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an Ongoing Observational IL-2 Clinical Trial: PROCLAIMSM. **Clinical Genitourinary Cancer**. **2016**. PMID: 27916626.
81. Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Recine F, Alva A, **Agarwal N**,

- Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY, RISC Investigators. Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. **Cancer Medicine**. 2016. PMID: 28000388.
82. Bailey EB, Merriman J, Maughan B, Poole A, Tantravahi SK, Agarwal AM, Batten JA, Patel SB, Pal SK, Stenejem DD, **Agarwal N**. Effect of treatment dose reductions in the setting of hang-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. **Journal of Oncology Pharmacy Practice**. 2017. PMID: 28436250.
  83. Kuzman JA, Stenejem DD, Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, **Agarwal N**. Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma. **BMC Urology**. 2017. PMID: 28056941.
  84. Gill D, Gaston D, Bailey E, Hahn A, Gupta S, Batten J, Alex A, Boucher K, Stenejem D, **Agarwal N**. Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. **Clinical Genitourinary Cancer**. 2017. PMID: 28131750.
  85. Pal SK, Ghate SR, Li N, Swallow E, Peoples M, Zichlin ML, Perez JR, **Agarwal N**, Vogelzang NJ. Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEERMedicare Database Analysis. **Clinical Genitourinary Cancer**. 2017. PMID: 28139444.
  86. De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, **Agarwal N**, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanavesaran R, Rini BI, Broom R, Yamamoto H, Kaymakcalan MD, Heng DY, Choueiri TK. Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. **Clinical Genitourinary Cancer**. 2017. PMID: 28254206.
  87. Narayan V, Keefe SM, Haas N, Wang L, Puzanov I, Putt ME, Catino A, Fang J, **Agarwal N**, Hyman D, Smith AM, Finkelman BS, Narayan HK, Ewer S, ElAmm C, Lenihan DJ, Ky B. Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. **Clinical Cancer Research**. 2017. PMID: 28196874.
  88. **Agarwal N**, Hahn AW, Gil DM, Farnham JM, Poole AI, Cannon-Albright L. Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen Deprivation Therapy in Prostate Cancer. **JAMA Oncology**. 2017. PMID: 28208175.
  89. Motzer RJ, Figlin RA, Martini JF, Hariharan S, **Agarwal N**, Li CX, Williams JA, Hutson TE. Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results from the RENAL EFFECT Trial. **Clinical Genitourinary Cancer**. 2017. PMID: 28330808.
  90. Gupta S, Greenberg S, Grimmitt J, Gaston D, **Agarwal N**, Lowrance W, Schiffman J, Kohlmann W. Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers. **Familial Cancer**. 2017. PMID: 28315974.
  91. Flaig TW, Plets M, Hussain MH, **Agarwal N**, Mitsiades N, Deshpande HA, Vaishampayan UN, Thomspson IM Jr. Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. **JAMA Oncology**. 2017. PMID: 28358937.

92. Maughan BL, Bailey E, Gill DM, **Agarwal N**. Incidence of Immune-Related Adverse Events with Program Death Receptor-1-and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers. **Frontiers in Oncology**. 2017. PMID: 28421161.
93. Hahn AW, Gill DM, Maughan B, Agarwal A, Arival L, Gupta S, Streeter J, Bailey E, Pal SK, **Agarwal N**. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. **Oncotarget**. 2017. PMID: 28431395.
94. Pal SK, Sonpavde G, **Agarwal N**, Vogelzang NJ, Srinivas S, Haas NB, Signoretti S, McGregor BA, Jones J, Lanman RB, Banks KC, Choueiri TK. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. **European Urology**. 2017. PMID: 28413127.
95. Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, Choueiri TK, Heng DYC. Characterizing the outcomes of metastatic papillary renal cell carcinoma. **Cancer Medicine**. 2017. PMID: 28414866.
96. Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN Jr, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM Jr, Twardowski PW, Van Veldhuizen PJ Jr, **Agarwal N**, Carducci MA, Monk JP, Quinn DI. Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration Resistant Prostate Cancer Treated on SWOG Study S0421. **Clinical Genitourinary Cancer**. 2017. PMID: 28579151.
97. Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Milller VA, **Agarwal N**, Shuch B, Choueiri TK, Chung JH. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. **European Urology**. 2017. PMID: 28592388.
98. Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, **Agarwal N**, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthoid DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. **European Urology Focus**. 2017. PMID: 28753879.
99. Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, **Agarwal N**, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K, Young Academic Urologists Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium group. Lack of

- Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. **European Urology Focus**. 2017. PMID: 28753897.
100. Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, De Giorgi U, Hussain S, Alva AS, Baniel J, **Agarwal N**, Rosenberg JE, Vaishampayan UN, Galsky MD, Yu EY, RISC Investigators. Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. **Clinical Genitourinary Cancer**. 2017. PMID: 28923700.
  101. Poole A, Gill D, Hahn AW, Johnson E, Carroll E, Boucher K, Nussenzweig R, Maughan B, **Agarwal N**. Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. **Clinical Genitourinary Cancer**. 2017. PMID: 28958675.
  102. Gupta S, Albertson D, Gaston D, Heilbrun ME, **Agarwal N**, Boucher K, Parnell TJ, Liu T, Morgans A, Madison R, Gowen K, Miller VA, Ross JS, Ali SM, Millis SZ. Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System. **Clinical Genitourinary Cancer**. 2017. Clin Genitourin Cancer. PMID: 28974397.
  103. Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Pal SK, De Giorgi U, Ladoire S, **Agarwal N**, Yu EY, Neigisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishapayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Belmunt J, Galsky MD, RISC Investigators. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: A Retrospective International Study of Invasive/advanced cancer of the urothelium (RISC). **Annals of Oncology**. 2017. PMID: 29077785.
  104. Vogelzang, NJ, Pal SK, Ghatge SR, Swallow E, Li N, Peoples M, Zichlin ML, Meiselbach MK, Perez JR, **Agarwal N**. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis. **Advances in Therapy**. 2017. PMID: 29076108.
  105. Cheng HH, Plets M, Li H, Higano CS, Tangen CM, **Agarwal N**, Vogelzang NJ, Hussain M, Thompson IM Jr, Tewari M, Yu EY. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. **The Prostate**. 2018. PMID: 29105802.
  106. Catino AB, Hubbard RA, Chirinos JA, Townsend R, Keefe S, Haas NB, Puzanov I, Fang JC, **Agarwal N**, Hyman D, Smith AM, Gordon M, Plappert T, Englefield V, Narayan V, Ewer S, ElAmm C, Lenihan D, Ky B. Longitudinal Assessment of Vascular Function with Sunitinib in Patients With Metastatic Renal Cell Carcinoma. **Circulation: Heart Failure**. 2018. PMID: 29664405.
  107. Hahn AW, Gill DM, Nussenzweig RH, Poole A, Farnham J, Cannon-Albright L, **Agarwal N**. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer. **Clinical Genitourinary Cancer**. 2018. PMID: 29674118.
  108. Stukalin I, Wells CJ, Fracon A, Pasini F, Porta C, Lalani AA, Srinivas S, Bowman AI, Brugarolas J, Lee JL, Donskov F, Beuselinck B, Bamias A, Rini BI, Sim HW, **Agarwal N**, Rha SY, Kanesvaran R, Choueiri TK, Heng DYC. Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database

- Consortium (IMDC). *Kidney Cancer (IOS Press)*. **2018**. Mar 30. DOI: 10.3233/KCA-170020.
109. Necchi A, Pond GR, Pal SK, **Agarwal N**, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthold DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD. Retrospective International Study of Invasive/Advanced Cancer of the Urothelium Group. Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. **Clinical Genitourinary Cancer**. **2018**. PMID: 29158079.
  110. **Agarwal N**, Pal SK, Hahn AW, Nussenzevig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Holmes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. **Cancer**. **2018**. PMID: 29517810.
  111. Hahn AW, Froerer C, VanAlstine S, Rathi N, Bailey EB, Stenehjem DD, **Agarwal N**. Targeting Bacteroides in Stool Microbiome and Response to Treatment with First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma. **Clinical Genitourinary Cancer**. **2018**. PMID: 29858123.
  112. Hale P, Hahn AW, Rathi N, Pal SK, Haaland B, **Agarwal N**. Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis. **Journal of Geriatric Oncology**. **2018**. PMID: 29861146.
  113. Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, **Agarwal N**. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data. **Journal of Managed Care & Specialty Pharmacy**. **2018**. PMID: 29799328.
  114. Hamieh L, Choueiri TK, Ogorek B, Khabibullin D, Rosebrock D, Livitz D, Fay A, Pignon JC, McDermott DF, **Agarwal N**, Gao W, Signoretti S, Kwiatkowski DJ. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. **PLOS Genetics**. **2018**. PMID: 30256787.
  115. Necchi A, Pond GR, Moschini M, Plimack ER, Niegisch G, Yu EY, Bamias A, **Agarwal N**, Vaishampayan U, Theodore C, Sridhar SS, Rosenberg JE, Bellmunt J, Gallina A, Colombo R, Montorsi F, Briganti A, Galsky MD. Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. **Clinical Genitourinary Cancer**. **2018**. PMID: 30292628.
  116. Twardowski PW, Tangen CM, Wu X, Plets MR, Plimack ER, **Agarwal N**, Vogelzang NJ, Wang J, Tao S, Thompson IM, Lara P. Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107. **Kidney Cancer**. **2017**. PMID: 30334014.
  117. Kroeger N, Li H, De Velasco G, Donskov F, Sim HW, Stuhler V, Wells JC, Stukalin I, Heide J, Bedke J, **Agarwal N**, Parekh H, Rini BI, Knox JJ, Pantuck A, Choueiri TK, Chin Heng DY. Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. **Clinical Genitourinary Cancer**. **2018**. PMID: 30341028.
  118. Del Bene G, Calabro F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, **Agarwal N**, Bamias A, Ladoire S, Necchi A,

- Vaishampayan UN, Niegisch G, Bellmunt J, Baniel J, Galsky MD, Sternberg CN. Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. **Frontiers in Oncology**. 2018. PMID: 30510914.
119. Maughan BL, Pal SK, Gill D, Boucher K, Martin C, Salgia M, Nussenzweig R, Liu T, Hawks JL, Batten J, Nachaegari G, Stephenson R, Lowrance W, Jones J, Dechet C, **Agarwal N**. Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. **The Oncologist**. 2018. PMID: 30575560.
  120. Hahn AW, Gill DM, Poole A, Nussenzweig RH, Wilson S, Farnham JM, Stephenson RA, Cannon-Albright LA, Maughan BL, **Agarwal N**. Germline Variant in *SLCO2B1* and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC). **Molecular Cancer Therapeutics**. 2019. PMID: 30587554.
  121. Sonpavde G\*, **Agarwal N\***, Pond GR\*, Nagy RJ, Nussenzweig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasz A, Lilly MB (**\*equal contribution**). Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. **Cancer**. 2019. PMID: 30620391.
  122. Stenhjem DD, Hahn AW, Gill DM, Albertson D, Gowrishankar B, Merriman J, Agarwal AM, Thodima V, Harrington EB, Au TH, Maughan BL, Houlsworth J, Pal SK, **Agarwal N**. Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. **Plos One**. 2019. PMID: 30682039.
  123. Twardowski P, Wong JYC, Pal SK, Maughan BL, Frankel PH, Franklin K, Junqueira M, Prajapati MR, Nachaegari G, Harwood D, **Agarwal N**. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. **Cancer Treatment and Research Communications**. 2018. PMID: 30682445.
  124. Hahn AW, Stenhjem D, Nussenzweig R, Carroll E, Bailey E, Batten J, Maughan BL, **Agarwal N**. Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. **Cancer Treatment and Research Communications**. 2019. PMID: 30743187.
  125. Hahn AW, Stenhjem DD, Alex AB, Gill DM, Cheng HH, Kessler ER, Chittoria N, Twardowski P, Vaishampayan U, **Agarwal N**. Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. **Urologic Oncology**. 2019. PMID: 30770300.
  126. Gulley JL, Borre M, Vogelzang NJ, Ng S, **Agarwal N**, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. **Journal of Clinical Oncology**. 2019. PMID: 30817251.
  127. Martinez Chanza N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, **Agarwal N**, Pal SK, Srinivas S, Carneiro BA, Heng

- DYC, Bosse D, Choueiri TK, Harshman LC. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. **Lancet Oncology**. 2019. PMID: 30827746.
128. Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, **Agarwal N**, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM registry. **Journal for Immunotherapy of Cancer**. 2019. PMID: 30917871.
129. Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U, Ladoire S, Theodore C, **Agarwal N**, Yu EY, Niegisch G, Sternberg CN, Srinivas S, Vaishampayan U, Necchi A, Lontos M, Rosenberg JE, Powles T, Bellmunt J, Galsky MD. The impact of Cisplatin-or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer (Epub ahead of print). **The Oncologist**. 2019. PMID: 30936379.
130. Chi KN, **Agarwal N**, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juarez Soto A, Merseburger AS, Ozguroglu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S, TITAN Investigators. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. **The New England Journal of Medicine**. 2019. PMID: 31150574.
131. Michaelson MD, Gupta S, **Agarwal N**, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Lechuga MJ, Valota O, Shepard DR. A Phase 1b Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors (Epub ahead of print). **The Oncologist**. 2019. PMID: 31171735.
132. Bandini M, Briganti A, Plimack ER, Niegisch G, Bamias A, **Agarwal N**, Sridhar SS, Sternberg CN, Vaishampayan U, Theodore C, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. **European Urology Oncology**. 2019. PMID: 31200838.
133. Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, Frampton GM, Bratslavsky G, Pal SK, Lee RJ, Necchi A, Gregg JP, Lara P Jr, Antonarakis ES, Miller VA, Ross JS, Ali SM, **Agarwal N**. Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. **JCO Precision Oncology**. 2019. PMID: 31218271.
134. Pederzoli F, Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, **Agarwal N**, Sridhar SS, Sternberg CN, Vaishampayan UN, Theodore C, Rosenberg JE, Harshman LC, Bellmunt J, Galsky MD, Gallina A, Salonia A, Montorsi F, Necchi A, RISC Investigators. Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. **European Urology**. 2019. PMID: 31303258.
135. Moschini M, Xylinas E, Zamboni S, Mattei A, Niegisch G, Yu EY, Bamias A, **Agarwal N**, Sridhar SS, Sternberg CN, Vaishampayan UN, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A, RISC Investigators. Efficacy of Surgery in the Primary

- Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. **European Urology Oncology**. **2019**. PMID: 31307962.
136. Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, **Agarwal N**. Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. **Journal of Geriatric Oncology**. **2019**. PMID: 31402176.
  137. Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, **Agarwal N**, Necchi A, Pal SK, Sternberg CN, Bellmunt J, Galsky MD, Harshman LC, RISC Investigators. Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. **European Urology Oncology**. **2019**. PMID: 31411990.
  138. Grivas P, Lalani AA, Pond GR, Nagy RJ, Faltas B, **Agarwal N**, Gupta SV, Drakaki A, Vaishampayan UN, Wang J, Barata PC, Gopalakrishnan D, Naik G, McGregor BA, Kiedrowski LA, Lanman RB, Sonpavde GP. Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. **European Urology Oncology**. **2019**. PMID: 31412004.
  139. Hahn AW, Drake C, Denmeade SR, Zakharia Y, Maughan BL, Kennedy E, Link C Jr, Vahanian N, Hammers H, **Agarwal N**. A Phase 1 Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. **The Oncologist**. **2019**. PMID: 32043778.
  140. **Agarwal N**, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Ozguroglu M, Juarez Soto A, Merseburger AS, Uemura H, Ye D, Given R, Cella D, Basch E, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi KN, TITAN investigators. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. **Lancet Oncology**. **2019**. PMID: 31578173.
  141. Hahn AW, Klaassen Z, **Agarwal N**, Haaland B, Esther J, Ye XY, Wang X, Pal SK, Wallis CJD. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. **European Urology Oncology**. **2019**. PMID: 31588018.
  142. Ledet EM, Lilly MB, Sonpavde G, Lin E, Nussenzweig RH, Barata PC, Yandell M, Nagy RJ, Kiedrowski L, **Agarwal N**, Sartor O. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. **The Oncologist**. **2019**. PMID: 32297439.
  143. **Agarwal N**, Nussenzweig RH, Hahn AW, Hoffman JM, Morton K, Gupta S, Batten J, Thorley J, Hawks JL, Santos VS, Nachaegari G, Wang X, Boucher KM, Haaland B, Maughan BL. Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer. **Clinical Cancer Research**. **2020**. PMID: 31937614.
  144. Miller NJ, Khaki AR, Diamantopoulos LN, Bilen MA, Santos V, **Agarwal N**, Morales-Barrera R, Devitt M, Nelson A, Holmes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez –Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Velho PI, Hahn N, Liu S, Buznego LA, Duran I, Moses M, Jain J, Murgic J, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Lyman GH, Grivas P. Histologic Subtypes and

- Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. **The Journal of Urology**. **2020**. PMID: 31971495.
145. Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, **Agarwal N**, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. **Clinical Cancer Research**. **2020**. PMID: 32034076.
  146. Wong RL, Duong MT, Tangen CM, **Agarwal N**, Cheng HH, Vogelzang NJ, Hussain M, Thompson IM JR, Quinn DI, Yu EY. Survival Outcomes and Risk Group Validation From SWOG S0925: A Randomized Phase II Study of Cixutumumab in New Metastatic Hormone-Sensitive Prostate Cancer. **Prostate Cancer and Prostatic Diseases**. **2020**. PMID: 32055002.
  147. Bandini M, Pederzoli F, Madison R, Briganti A, Ross JS, Niegisch G, Yu EY, Bamias A, **Agarwal N**, Sridhar SS, Rosenberg JE, Bellmunt J, Pal SK, Galsky MD, Luciano R, Gallina A, Salonia A, Montorsi F, Ali SM, Chung JH, Necchi A. Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. **Clinical Genitourinary Cancer**. **2020**. PMID: 32144050.
  148. Tward JD, O'Neil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, **Agarwal N**, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet C. Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. **Clinical Genitourinary Cancer**. **2020**. PMID: 32335059.
  149. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, **Agarwal N**, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. **The New England Journal of Medicine**. **2020**. PMID: 32343890.
  150. Antonarakis ES, Isaacsson Velho P, Fu W, Wang H, **Agarwal N**, Sacristan Santos V, Maughan BL, Pili R, Adra N, Sternberg CN, Vlachostergios PJ, Tagawa ST, Bryce AH, McNatty AL, Reichert ZR, Dreicer R, Sartor O, Lotan TL, Hussain M. CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. **JCO Precision Oncology**. **2020**. PMID: 32462107.
  151. Ravi P, Mantia C, Su C, Sorenson K, Elhag D, Rathi N, Bakouny Z, **Agarwal N**, Zakharia Y, Costello BA, McKay RR, Narayan V, Alva A, McGregor BA, Gao X, McDermott DF, Choueiri TK. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. **JAMA Oncology**. **2020**. PMID: 32469396.
  152. McGregor BA, Gordon M, Flippot R, **Agarwal N**, George S, Quinn DI, Rogalski M, Hawthorne T, Keler T, Choueiri TK. Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. **Investigational New Drugs**. **2020**. PMID: 32472319.
  153. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA,

- Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, **Agarwal N**, Jonasch E, Koh MY. Macrophage HIF-1 $\alpha$  Is an Independent Prognostic Indicator in Kidney Cancer. **Clinical Cancer Research**. 2020. PMID: 32586940.
154. Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, **Agarwal N**. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. **European Urology**. 2020. PMID: 32624276.
155. Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, **Agarwal N**, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Sternberg CN, Bellmunt J, Baniel J, Niegisch G. Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. **Urologic Oncology**. 2020. PMID: 32660788.
156. Moses M, Niu A, Lilly MB, Hahn AW, Nussenzveig R, Ledet E, Manogue C, Cotogno P, Lewis B, Layton J, **Agarwal N**, Sartor O, Barata PC. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. **Cancer Treatment and Research Communications**. 2020. PMID: 32702615.
157. Barata P, **Agarwal N**, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R, Stein C, Kiedrowski L, Saylor P, Sartor O. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. **Journal for Immunotherapy of Cancer**. 2020. PMID: 32788235.
158. Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, Bossi A, den Eertwegh AJMV, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Danielli R, Franke FA, Sundar S, **Agarwal N**, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, McHenry MB, Chen A, Logothetis C; CA184-043, Investigators. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Post docetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. **European Urology**. 2020. PMID: 32811715.
159. Necchi A, Madison R, Pal SK, Ross JS, **Agarwal N**, Sonpavde G, Joshi M, Yin M, Miller VA, Grivas P, Chung JH, Ali SM. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. **European Urology Focus**. 2020. PMID: 32861617.
160. Sokol ES, Pavlick D, Khiabani H, Frampton GM, Ross JS, Gregg JP, Lara PN, Oesterreich S, **Agarwal N**, Necchi A, Miller VA, Alexander B, Ali SM, Ganesan S, Chung JH. Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. **JCO Precision Oncology**. 2020. PMID: 32903788.
161. Boyle JL, Hahn AW, Kapron AL, Kohlmann W, Greenberg SE, Parnell TJ, Teerlink CC, Maughan BL, Feng BJ, Cannon-Albright L, **Agarwal N\***, Cooney KA\* (\***co-corresponding author**). Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer. **JCO Precision Oncology**. 2020. PMID: 32923906.

162. Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, **Agarwal N**, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. **The New England Journal of Medicine**. 2020. PMID: 32955174.
163. Swami U, Haaland B, Kessel A, Nussenzveig R, Maughan BL, Esther J, Sirohi D, Pal SK, Grivas P, **Agarwal N**. Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum-Refractory Advanced Urothelial Carcinoma. **The Journal of Urology**. 2020. PMID: 33080152.
164. Cannon-Albright LA, Stevens J, Teerlink CC, **Agarwal N**. The HOXB13 p.Gly84Glu variant observed in an extended five generation high-risk prostate cancer pedigree supports risk association for multiple cancer sites. **Cancer Epidemiology**. 2020. PMID: 33099213.
165. Tripathi A, Lin E, Xie W, Flaifel A, Steinharter JA, Stern Gatof EN, Bouchard G, Fleischer JH, Martinez-Chanza N, Gray C, Mantia C, Thompson L, Wei XX, Giannakis M, McGregor BA, Choueiri TK, **Agarwal N**, McDermott DF, Signoretti S, Harshman LC. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. **Journal for Immunotherapy of Cancer**. 2020. PMID: 33177176.
166. Sena LA, Fountain J, Isaacsson Velho P, Lim SJ, Wang H, Nizialek E, Rathi N, Nussenzveig R, Maughan BL, Velez MG, Ashkar R, Larson AC, Pritchard CC, Adra N, Bryce AH, **Agarwal N**, Pardoll DM, Eshleman JR, Lotan TL, Antonarakis ES. Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair-deficient prostate cancer. **The Oncologist**. 2020. PMID: 33215787.
167. Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V, Park J, Alva A, Bilen MA, Stewart T, Santos V, **Agarwal N**, Jain J, Zakharia Y, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. **European Urology Oncology**. 2021. PMID: 33423945.
168. Goldkorn A, Tangen C, Plets M, Morrison GJ, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, Harzstark AL, Kohli M, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN Jr, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM Jr, **Agarwal N**. Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). **Clinical Cancer Research**. 2021. PMID: 33500355.
169. Coletta AM, Rose NB, Johnson AF, Moxon DS, Trapp SK, Walker D, White S, Ulrich CM, **Agarwal N**, Oza S, Zingg RW, Hansen PA. The impact of a hospital-based exercise oncology program on cancer treatment-related side effects among rural cancer survivors. **Supportive Care in Cancer**. 2021. PMID: 33502590.
170. Swami U, Grivas P, Pal SK, **Agarwal N**. Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience. **Cancer Treatment and Research Communications**. 2021. PMID: 33549986.

171. Esagian SM, Khaki AR, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, **Agarwal N**, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Msaouel P, Koshkin VS, Grivas P. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. **BJU International**. **2021**. PMID: 33556233.
172. Denmeade SR, Wang H, **Agarwal N**, Smith DC, Schweizer MT, Stein MN, Assikis V, Twardowski PW, Flaig TW, Szmulewitz RZ, Holzbeierlein JM, Hauke RJ, Sonpavde G, Garcia JA, Hussain A, Sartor O, Mao S, Cao H, Fu W, Wang T, Abdallah R, Lim SJ, Bolejack V, Paller CJ, Carducci MA, Markowski MC, Eisenberger MA, Antonarakis ES. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. **Journal of Clinical Oncology**. **2021**. PMID: 33617303.
173. Palmboos PL, Daignault-Newton S, Tomlins SA, **Agarwal N**, Twardowski P, Morgans AK, Kelly WK, Arora VK, Antonarakis ES, Siddiqui J, Jacobson J, Davenport MS, Robinson DR, Chinnaiyan AM, Knudsen KE, Hussain M. A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone Sensitive Prostate Cancer (mHSPC). **Clinical Cancer Research**. **2021**. PMID: 33727260.
174. Parikh M, Liu C, Wu CY, Evans CP, Dall'Era M, Robles D, Lara PN, **Agarwal N**, Gao AC, Pan CX. Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. **Scientific Reports**. **2021**. PMID: 33737681.
175. Harrison MR, Costello BA, Bhavsar NA, Vaishampayan U, Pal SK, Zakharia Y, Jim HSL, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK, Appleman LJ, Gartrell BA, Hussain A, Stadler WM, **Agarwal N**, Pachynski RK, Hutson TE, Hammers HJ, Ryan CW, Inman BA, Mardekian J, Borham A, George DJ. Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). **Cancer**. **2021**. PMID: 33765337.
176. Choueiri TK, Zakharia Y, Pal S, Kocsis J, Pachynski R, Poprach A, Nixon AB, Liu Y, Starr M, Lyu J, Owzar K, deShazo M, Lara P, Geczi L, Ho TH, Walsh M, Adams B, Robertson L, Darif M, Theuer C, **Agarwal N**. Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). **The Oncologist**. **2021**. PMID: 33829609.
177. Hutson TE, Michaelson MD, Kuzel TM, **Agarwal N**, Molina AM, Hsieh JJ, Vaishampayan UN, Xie R, Bapat U, Ye W, Jain RK, Fishman MN. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. **European Urology**. **2021**. PMID: 33867192.
178. Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez A, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Brookman-May S, Mundle SD, McCarthy SA, Larsen JS, Sun W, Bevans KB, Zhang K, Bandyopadhyay N, **Agarwal N**. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. **Journal of Clinical Oncology**. **2021**. PMID: 33914595.

179. Tagawa ST, Balar AV, Petrylak DP, Kalebastay AR, Loriot Y, Fléchon A, Jain RK, **Agarwal N**, Bupathi M, Barthelemy P, Beuzebec P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Hong Q, Goswami T, Itri LM, Grivas P. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. **Journal of Clinical Oncology**. **2021**. PMID: 33929895.
180. Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, **Agarwal N**, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ. A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. **BMC Cancer**. **2021**. PMID: 33957901.
181. **Agarwal N**, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Özgüroğlu M, Soto AJ, Merseburger AS, Uemura H, Ye D, Given R, Basch E, Miladinovic B, Lopez-Gitlitz A, Chi KN. Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study. **The Journal of Urology**. **2021**. PMID: 34039013
182. Cannon-Albright LA, Teerlink CC, Stevens J, Huang FW, Sipeky C, Schleutker J, Hernandez R, Facelli J, **Agarwal N**, Trump DL. A Rare Variant in ERF (rs144812092) Predisposes to Prostate and Bladder Cancers in an Extended Pedigree. **Cancers (Basel)**. **2021**. PMID: 34063511.
183. Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, Choueiri TK, **Agarwal N\***, Pal SK\* (\*co-corresponding author). Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. **Clinical Cancer Research**. **2021**. PMID: 34130999.
184. Lin E, Hahn AW, Nussenzweig RH, Wesolowski S, Sayegh N, Maughan BL, McFarland T, Rathi N, Sirohi D, Sonpavde G, Swami U, Kohli M, Rich T, Sartor O, Yandell M, **Agarwal N**. Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. **The Oncologist**. **2021**. PMID: 34157173.
185. Costello BA, Bhavsar NA, Zakharia Y, Pal SK, Vaishampayan U, Jim H, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK, Appleman LJ, Gartrell BA, Hussain A, Stadler WM, **Agarwal N**, Pachynski RK, Hutson TE, Hammers HJ, Ryan CW, Mardekian J, Borham A, George DJ, Harrison MR. A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. **Clinical Genitourinary Cancer**. **2021**. PMID: 34364796.
186. Maughan BL, Kessel A, McFarland TR, Sayegh N, Nussenzweig R, Hahn AW, Hoffman JM, Morton K, Sirohi D, Kohli M, Swami U, Boucher K, Haaland B, **Agarwal N**. Radium-223 plus Enzalutamide versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. **The Oncologist**. **2021**. PMID: 34423501.
187. Evans R, Hawkins N, Dequen-O'Byrne P, McCrea C, Muston D, Gresty C, Ghate SR, Fan L, Hettle R, Abrams KR, de Bono J, Hussain M, **Agarwal N**. Exploring the Impact

- of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). **Target Oncology**. 2021. PMID: 34478046.
188. Pal SK, McGregor B, Suárez C, Tsao CK, Kelly W, Vaishampayan U, Pagliaro L, Maughan BL, Loriot Y, Castellano D, Srinivas S, McKay RR, Dreicer R, Hutson T, Dubey S, Werneke S, Panneerselvam A, Curran D, Scheffold C, Choueiri TK, **Agarwal N**. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. **Journal of Clinical Oncology**. 2021. PMID: 34491815.
  189. Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, **Agarwal N**, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. **BJU International**. 2021. PMID: 34597472.
  190. Penson DF, Armstrong AJ, Concepcion RS, **Agarwal N**, Olsson CA, Karsh LI, Dunshee CJ, Duggan W, Shen Q, Sugg J, Haas GP, Higano CS. Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. **Prostate Cancer and Prostatic Diseases**. 2021. PMID: 34621011.
  191. Sartor O, George D, Tombal B, **Agarwal N**, Higano CS, Sternberg CN, Miller K, Jiao X, Guo H, Sandström P, Bruno A, Verhopen F, Saad F, Shore N. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. **Future Oncology**. 2022. PMID: 34636627.
  192. Swami U, Sinnott JA, Haaland B, Sayegh N, McFarland TR, Tripathi N, Maughan BL, Rathi N, Sirohi D, Nussenzveig R, Kohli M, Pal SK, **Agarwal N**. Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. **Cancers (Basel)**. 2021. PMID: 34638435.
  193. Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, Xu W, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barthélémy P, **Agarwal N**, McKay RR, Brastianos PK, Krajewski KM, Albigès L, Harshman LC, Choueiri TK. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. **JAMA Oncology**. 2021. PMID: 34673916.
  194. Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, **Agarwal N**, Kessel A, Bryce A, Nafissi N, Barata P, Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES. Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. **JCO Precision Oncology**. 2021. PMID: 34778690.
  195. Talukder R, Makrakis D, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR,

- Santos VS, **Agarwal N**, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lorenzo GD, Joshi M, Velho PI, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. **Clinical Genitourinary Cancer**. 2022. PMID: 35078711.
196. Sirohi D, Chipman J, Barry M, Albertson D, Mahlow J, Liu T, Raps E, Haaland B, Sayegh N, Li H, Rathi N, Sharma P, **Agarwal N**, Knudsen B. Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups. **Clinical Genitourinary Cancer**. 2022. PMID: 35125301.
197. George DJ, **Agarwal N**, Sartor O, Sternberg CN, Tombal B, Saad F, Miller K, Constantinovici N, Guo H, Reeves J, Jiao X, Sandström P, Verholen F, Higano CS, Shore N. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). **Prostate Cancer and Prostatic Diseases**. 2022. PMID: 35190653.
198. Freeman MN, Jang A, Zhu J, Sanati F, Nandagopal L, Ravindranathan D, Desai A, Phone A, Nussenzveig R, Jaeger E, Caputo SA, Koshkin VS, Swami U, Basu A, Bilen MA, **Agarwal N**, Sartor O, Burgess EF, Barata PC. Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer. **The Oncologist**. 2022. PMID: 35274720.
199. Graf RP, Fisher V, Weberpals J, Gjoerup O, Tierno MB, Huang RSP, Sayegh N, Lin DI, Raskina K, Schrock AB, Severson E, Haberberger JF, Ross JS, Creeden J, Levy MA, Alexander BM, Oxnard GR, **Agarwal N**. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. **JAMA Network Open**. 2022. PMID: 35357449.
200. T'jollyn H, Ackaert O, Chien C, Lopez-Gitlitz A, McCarthy S, Ruixo CP, Karsh L, Chi K, Chowdhury S, Ruixo JP, **Agarwal N**. Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. **Cancer Chemotherapy and Pharmacology**. 2022. PMID: 35366072.
201. **Agarwal N**, Tangen CM, Hussain MHA, Gupta S, Plets M, Lara PN, Harzstark AL, Twardowski PW, Paller CJ, Zylla D, Zibelman MR, Levine E, Roth BJ, Goldkorn A, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM Jr, Quinn DI. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). **Journal of Clinical Oncology**. 2022. PMID: 35446628.
202. **Agarwal N**, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). **Lancet Oncology**. 2022. PMID: 35690072.
203. Makrakis D, Talukder R, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart

- TF, McKay RR, Tripathi N, **Agarwal N**, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Jang A, Barata P, Sonpavde G, Yu EY, Montgomery RB, Grivas P, Khaki AR. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. **Clinical Genitourinary Cancer**. 2022. PMID: 35778337.
204. Sayegh N, Tripathi N, Nussenzveig RH, Thomas VM, Tandar C, Goel D, Nordblad B, Sahu KK, Li H, L Maughan B, **Agarwal N\***, Swami U\* (**\*co-corresponding author**). Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. **European Urology Focus**. 2022. PMID: 35835693.
205. Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, **Agarwal N\***, Sirohi D\* (**\*co-corresponding author**). Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma. **Urologic Oncology**. 2022. PMID: 35918248.
206. Zimmerman R, Bilen MA, Heath EI, Nandagopal L, Swami U, Kessel A, Jaeger E, Wesolowski S, Hernanadez EJ, Chipman J, Mack A, Ravindranathan D, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Lilly MB, Sartor AO, **Agarwal N\***, Barata PC\* (**\*co-corresponding author**). Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race. **The Oncologist**. 2022. PMID: 36036607.
207. Chi KN, Barnicle A, Sibilla C, Lai Z, Corcoran C, Barrett JC, Adelman CA, Qiu P, Easter A, Dearden S, Oxnard GR, **Agarwal N**, Azad A, de Bono J, Mateo J, Olmos D, Thierry-Vuillemin A, Harrington EA. Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. **Clinical Cancer Research**. 2022. PMID: 36043882.
208. Tannir NM, **Agarwal N**, Porta C, Lawrence NJ, Motzer R, McGregor B, Lee RJ, Jain RK, Davis N, Appleman LJ, Goodman O Jr, Stadler WM, Gandhi S, Geynisman DM, Iacovelli R, Mellado B, Sepúlveda Sánchez JM, Figlin R, Powles T, Akella L, Orford K, Escudier B. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. **JAMA Oncology**. 2022. PMID: 36048457.
209. Swami U, Graf RP, Nussenzveig RH, Fisher V, Tukachinsky H, Schrock AB, Li G, Ross JS, Sayegh N, Tripathi N, Mathew Thomas V, Oxnard GR, Antonarakis ES, **Agarwal N**. SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer. **Clinical Cancer Research**. 2022. PMID: 36088616.
210. Green YS, Ferreira Dos Santos MC, Fuja DG, Reichert EC, Campos AR, Cowman SJ, Acuña Pilarte K, Kohan J, Tripp SR, Leibold EA, Sirohi D, **Agarwal N**, Liu X, Koh MY. ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma. **Oncogene**. 2022. PMID: 36097192.

211. Li H, Sahu KK, Kumar SA, Nordblad B, Sayegh N, Tripathi N, Thomas VM, Gupta S, Maughan BL, **Agarwal N**, Swami U. A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers. **Heliyon**. **2022**. PMID: 36120495.
212. Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, **Agarwal N**, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Wright JL, Yu EY, Montgomery RB, Hsieh AC, Grivas P, Khaki AR. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. **Clinical Genitourinary Cancer**. **2022**. PMID: 36155169.
213. Swami U, Zimmerman RM, Nussenzweig RH, Hernandez EJ, Jo Y, Sayegh N, Wesolowski S, Kiedrowski LA, Barata PC, Lemmon GH, Bilen MA, Heath EI, Nandagopal L, Babiker HM, Pal SK, Lilly M, Maughan BL, Haaland B, Yandell M, Sartor O, **Agarwal N**. Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA. **Frontiers in Oncology**. **2022**. PMID: 36185208.
214. Swami U, Sayegh N, Jo Y, Haaland B, McFarland TR, Nussenzweig RH, Goel D, Sirohi D, Hahn AW, Maughan BL, Goldkorn A, **Agarwal N**. External validation of association of baseline circulating tumor cell counts with survival outcomes in men with metastatic castration-sensitive prostate cancer. **Molecular Cancer Therapeutics**. **2022**. PMID: 36198026.
215. Bakouny Z, El Zarif T, Dudani S, Connor Wells J, Gan CL, Donskov F, Shapiro J, Davis ID, Parnis F, Ravi P, Steinharter JA, **Agarwal N**, Alva A, Wood L, Kapoor A, Ruiz Morales JM, Kollmannsberger C, Beuselinck B, Xie W, Heng DYC, Choueiri TK. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. **European Urology**. **2022**. PMID: 36272943.
216. Matsubara N, de Bono J, Olmos D, Procopio G, Kawakami S, Ürün Y, van Alphen R, Flechon A, Carducci MA, Choi YD, Hotte SJ, Korbenfeld E, Kramer G, **Agarwal N**, Chi KN, Dearden S, Gresty C, Kang J, Poehlein C, Harrington EA, Hussain M. Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA. **Clinical Cancer Research**. **2022**. PMID: 36318705.
217. Su CT, Nizialek E, Berchuck JE, Vlachostergios PJ, Ashkar R, Sokolova A, Barata PC, Aggarwal RR, McKay RR, **Agarwal N**, McClure HM, Nafissi N, Bryce AH, Sartor O, Sayegh N, Cheng HH, Adra N, Sternberg CN, Taplin ME, Cieslik M, Alva AS, Antonarakis ES. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer. **The Prostate**. **2022**. PMID: 36382533.

218. Winter JM, Fresenius HL, Cunningham CN, Wei P, Keys HR, Berg J, Bott A, Yadav T, Ryan J, Sirohi D, Tripp SR, Barta P, **Agarwal N**, Letai A, Sabatini DM, Wohlever ML, Rutter J. Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction. **Elife**. **2022**. PMID: 36409067.
219. Makrakis D, Bakaloudi DR, Talukder R, Lin GI, Diamantopoulos LN, Jindal T, Vather-Wu N, Zakharia Y, Tripathi N, **Agarwal N**, Dawsey S, Gupta S, Lu E, Drakaki A, Liu S, Zakopoulou R, Bamias A, Fulgenzi CM, Cortellini A, Pinato D, Barata P, Grivas P, Khaki AR, Koshkin VS. Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. **Clinical Genitourinary Cancer**. **2022**. PMID: 36481176.
220. Chawla NS, Sayegh N, Tripathi N, Govindarajan A, Zengin ZB, Phillip EJ, Dizman N, Meza L, Muddasani R, Chehrazi-Raffle A, Malhotra J, Hsu J, **Agarwal N**, Pal SK, Tripathi A. Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors. **Clinical Genitourinary Cancer**. **2022**. PMID: 36509613.
221. McFarland TR, Mathew Thomas V, Nussenzveig R, Gebrael G, Sayegh N, Tripathi N, Sahu KK, Goel D, Maughan BL, Sirohi D, **Agarwal N\***, Swami U\* (**\*co-corresponding author**). Detection of BRCA1, and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting. **Biomedicines**. **2022**. PMID: 36551924.
222. Takemura K, Navani V, Ernst MS, Wells JC, Meza L, Pal SK, Lee JL, Li H, **Agarwal N**, Alva AS, Hansen AR, Basappa NS, Szabados B, Powles T, Tran B, Hocking CM, Beuselinck B, Yuasa T, Choueiri TK, Heng DY. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. **The Journal of Urology**. **2022**. PMID: 36573926.
223. Swaby J, Aggarwal A, Batra A, Jain A, Seth L, Stabellini N, Bittencourt MS, Leong D, Klaassen Z, Barata P, Sayegh N, **Agarwal N**, Terris M, Guha A. Association of Androgen Deprivation Therapy with Metabolic Disease in Prostate Cancer Patients: An Updated Meta-Analysis. **Clinical Genitourinary Cancer**. **2022**. PMID: 36621463.
224. Swami U, Hong A, El-Chaar NN, Ramaswamy K, Diessner BJ, Blauer-Peterson CJ, Sandin R, Nimke D, **Agarwal N**. The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer. **The Journal of Urology**. **2023**. PMID: 36789668.
225. Lim EA, Schweizer MT, Chi KN, Aggarwal R, **Agarwal N**, Gulley J, Attiyeh E, Greger J, Wu S, Jaiprasart P, Loffredo J, Bandyopadhyay N, Xie H, Hansen AR. Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. **Clinical Genitourinary Cancer**. **2023**. PMID: 36948922.
226. Li H, Sahu KK, Brundage J, Benson M, Swami U, Boucher KM, Gupta S, Hawks J, Sirohi D, **Agarwal N\***, Maughan BL\* (**\*co-corresponding author**). Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma. **The Oncologist**. **2023**. PMID: 36952231.

227. Cannon-Albright LA, Stevens J, Facelli JC, Teerlink CC, Allen-Brady K, **Agarwal N**. High-Risk Pedigree Study Identifies LRBA (rs62346982) as a Likely Predisposition Variant for Prostate Cancer. **Cancers (Basel)**. **2023**. PMID: 37046747.
228. Lara PN Jr, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Vogelzang NJ, Thompson I, **Agarwal N**. Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. **European Urology**. **2023**. PMID: 37085425.
229. Swami U, Aggarwal H, Zhou M, Jiang S, Kim J, Li W, Laliberte F, Emond B, **Agarwal N**. Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data. **Clinical Genitourinary Cancer**. **2023**. PMID: 37248148.
230. **Agarwal N**, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, Giorgi UD, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschabitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K . Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. **The Lancet**. **2023**. PMID: 37285865.
231. Duarte C, Hu J, Beuselinck B, Panian J, Weise N, Dizman N, Collier KA, Rath N, Li H, Elias R, Martinez-Chanza N, Rose TL, Harshman LC, Gopalakrishnan D, Vaishampayan U, Zakharia Y, Narayan V, Carneiro BA, Mega A, Singla N, Meguid C, George S, Brugarolas J, **Agarwal N**, Mortazavi A, Pal S, McKay RR, Lam ET. Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study. **EClinicalMedicine**. **2023**. PMID: 37304495.
232. Chung BH, Huang J, Uemura H, Choi YD, Ye ZQ, Suzuki H, Kang TW, He DL, Joung JY, Brookman-May SD, McCarthy S, Bhaumik A, Singh A, Mundle S, Chowdhury S, **Agarwal N**, Ye DW, Chi KN, Uemura H. Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial. **Asian Journal of Andrology**. **2023**. PMID: 37322621.
233. Bakaloudi DR, Talukder R, Lin GI, Makrakis D, Diamantopoulos LN, Tripathi N, **Agarwal N**, Zakopoulou R, Bamias A, Brown JR, Pinato DJ, Korolewicz J, Jindal T, Koshkin VS, Murgić J, Miletić M, Frobe A, Johnson J, Zakharia Y, Drakaki A, Rodriguez-Vida A, Rey-Cárdenas M, Castellano D, Buznego LA, Duran I, Carballeira CC, Barrera RM, Marmorejo D, McKay RR, Stewart T, Gupta S, Ruplin AT, Yu EY, Khaki AR, Grivas P. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience. **Clinical Genitourinary Cancer**. **2023**. PMID: 37414620.
234. Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, Li H, Sahu KK, Strivastava A, McFarland T, Maughan BL, Swami U, **Agarwal N**. Survival outcomes of real-world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors. **Prostate Cancer and Prostatic Diseases**. **2023**. PMID: 37460732.

235. Dizman N, Govindarajan A, Zengin ZB, Meza L, Tripathi N, Sayegh N, Castro DV, Chan EH, Lee KO, Prajapati S, Feng M, Loo V, Pace M, O'Brien S, Bailey E, Barragan-Carrillo R, Chehrazi-Raffle A, Hsu J, Li X, **Agarwal N**, Pal SK. Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma. **Clinical Genitourinary Cancer**. 2023. PMID: 37495481.
236. Gebrael G, Sahu KK, Chigarira B, Tripathi N, Mathew Thomas V, Sayegh N, Maughan BL, **Agarwal N**, Swami U, Li H. Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0. **Cancers (Basel)**. 2023. PMID: 37509379.
237. Ryan CW, Tangen CM, Heath EI, Stein MN, Meng MV, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, **Agarwal N**, Uzzo RG, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Thompson IM Jr, Lara PN Jr. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. **The Lancet**. 2023. PMID: 37524096.
238. Sayegh N, Swami U, Jo Y, Gebrael G, Haaland B, Gupta S, Plets M, Hussain MHA, Quinn DI, Lara PN Jr, Thompson IM Jr, **Agarwal N**. Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial. **JAMA Network Open**. 2023. PMID: 37526936.
239. Chehrazi-Raffle A, Tukachinsky H, Toye E, Sivakumar S, Schrock AB, Bergom HE, Ebrahimi H, Pal S, Dorff T, **Agarwal N**, Mahal BA, Oxnard GR, Hwang J, Antonarakis ES. Unique spectrum of activating BRAF alterations in prostate cancer. **Clinical Cancer Research**. 2023. PMID: 37477913.
240. Merseburger AS, **Agarwal N**, Bhaumik A, Lefresne F, Karsh LI, Pereira de Santana Gomes AJ, Soto AJ, Given RW, Brookman-May SD, Mundle SD, McCarthy SA, Uemura H, Chowdhury S, Chi KN, Bjartell A. Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study. **European Journal of Cancer**. 2023. PMID: 37708629.
241. Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Thomas VM, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, **Agarwal N**, Swami U, Maughan BL. Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors. **Urology Practice**. 2023. PMID: 37903742.
242. Shen J, Chowdhury S, **Agarwal N**, Karsh LI, Oudard S, Gartrell BA, Feyerabend S, Saad F, Pieczonka CM, Chi KN, Brookman-May SD, Rooney B, Bhaumik A, McCarthy SA, Bevans KB, Mundle SD, Small EJ, Smith MR, Graff JN. Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. **British Journal of Cancer**. 2023. PMID: 37951974.
243. Li H, Sahu KK, Kumar SA, Tripathi N, Sayegh N, Nordblad B, Chigarira B, Gupta S, Maughan BL, **Agarwal N**, Swami U. Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural Areas. **Cancers (Basel)**. 2023. PMID: 37958345.

244. Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, **Agarwal N**, Olmos D, Thiery-Vuillemin A, Özgüroğlu M, Mehra N, Matsubara N, Young Joung J, Padua C, Korbenfeld E, Kang J, Marshall H, Lai Z, Barnicle A, Poehlein C, Lukashchuk N, Hussain M. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. **Journal of Clinical Oncology**. **2023**. PMID: 37963304.
245. Freedland SJ, Nair S, Lin X, Karsh L, Pieczonka C, Potluri R, Brookman-May SD, Mundle SD, Fleming S, **Agarwal N**. A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients. **World Journal of Urology**. **2023**. PMID: 37966506.
246. Ma TM, **Agarwal N**, Mahal B, Barragan-Carrillo R, Spratt D, Rettig MB, Valle LF, Steinberg ML, Garraway I, Vapiwala N, Xiang M, Kishan AU. Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer. **JAMA Network Open**. **2023**. PMID: 38039002.
247. Fizazi K\*, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, **Agarwal N\*** (**\*equal contribution**). First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. **Nature Medicine**. **2024**. PMID: 38049622.
248. Small EJ, Chi KN, Chowdhury S, Bevans KB, Bhaumik A, Saad F, Chung BH, Karsh LI, Oudard S, De Porre P, Brookman-May SD, McCarthy SA, Mundle SD, Uemura H, Smith MR, **Agarwal N**. Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer. **European Urology Oncology**. **2023**. PMID: 38072759.
249. Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, **Agarwal N**, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. **European Urology Oncology**. **2023**. PMID: 38072760.
250. Chowdhury S, Bjartell A, **Agarwal N**, Chung BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS, Özgüroğlu M, Soto AJ, Uemura H, Ye DW, Brookman-May SD, Londhe A, Bhaumik A, Mundle SD, Larsen JS, McCarthy SA, Chi KN. Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study. **Future Oncology**. **2023**. PMID: 38126311.
251. Miller EJ, Rose TL, Maughan BL, Milowsky MI, Bilen MA, Carthon BC, Gao X, Rapisuwon S, Zhao Q, Yu M, **Agarwal N**, Galsky MD. Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade. **Cancer**. **2024**. PMID: 38180804.
252. Abida W, Hahn AW, Shore N, **Agarwal N**, Sieber P, Smith MR, Dorff T, Monk JP, Rettig MB, Patel R, Page A, Duff M, Xu R, Wang J, Barkund S, Pankov A, Wang A, Junttila M, Multani PS, Daemen A, Chow Maneval E, Logothetis CJ, Morris MJ. Phase 1

- Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing on Enzalutamide. **Clinical Cancer Research**. 2024. PMID: 38226958.
253. Grivas P, Pouessel D, Park CH, Barthelemy P, Bupathi M, Petrylak DP, **Agarwal N**, Gupta S, Fléchon A, Ramamurthy C, Davis NB, Recio-Boiles A, Sternberg CN, Bhatia A, Pichardo C, Sierecki M, Tonelli J, Zhou H, Tagawa ST, Loriot Y. Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3. **Journal of Clinical Oncology**. 2024. PMID: 38261969.
254. Mahlow J, Barry M, Albertson DJ, Jo YJ, Balatico M, Seator T, Gebrael G, Kumar SA, Sayegh N, Tripathi N, **Agarwal N**, Swami U, Sirohi D. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway. **Human Pathology**. 2024. PMID: 38278448.
255. Takemura K, Lemelin A, Ernst MS, Wells JC, Saliby RM, El Zarif T, Labaki C, Basappa NS, Szabados B, Powles T, Davis ID, Wood LA, Lalani AA, McKay RR, Lee JL, Meza L, Pal SK, Donskov F, Yuasa T, Beuselinck B, Gebrael G, **Agarwal N**, Choueiri TK, Heng DY. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. **European Urology**. 2024. PMID: 38290965.
256. Guram K, Huang J, Mouchati C, Abdallah N, Jani C, Navani V, Xie W, El Zarif T, Adib E, Gebrael G, **Agarwal N**, Li H, Labaki C, Labban M, Ruiz Morales JM, Choueiri TK, Chin Heng DY, Mittal A, Hansen AR, Rose BS, McKay RR. Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database. **Cancer**. 2024. PMID: 38297953.
257. Lara PN Jr, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Thompson I, **Agarwal N**. Markers of bone metabolism and overall survival in men with bone-metastatic hormone-sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. **Prostate Cancer and Prostatic Diseases**. 2024. PMID: 38424319.
258. Sahu KK, Li H, Mathew Thomas V, Benson M, Boucher K, Gupta S, Kohli M, Swami U, **Agarwal N\***, Maughan BL\* (\*co-corresponding author). A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR). **The Oncologist**. 2024. PMID: 38452035.
259. Roy S, Saad F, Malone S, **Agarwal N**, Mohamad O, Morgan SC, Malone J, Swami U, Jia AY, Gebrael G, Mendiratta P, Brown JR, Rao SK, Sun Y, Wallis CJD, Chi KN, Chowdhury S, Kishan AU, Spratt DE. Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study. **European Urology**. 2024. PMID: 38485300.
260. **Agarwal N**, Castellano D, Alonso-Gordoa T, Arranz Arijia JA, Colomba E, Gravis G, Mourey L, Oudard S, Fléchon A, González M, Rey PM, Schweizer MT, Gallardo E, Johnston E, Balar A, Haddad N, Appiah AK, Nacerddine K, Piulats JM. A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-

- Resistant Prostate Cancer: Results from CYCLONE 1. **Clinical Cancer Research**. 2024. PMID: 38512117.
261. Parikh M, Tangen C, Hussain MHA, Gupta S, Callis S, Jo Y, Harzstark A, Paller CJ, George S, Zibelman MR, Cheng HH, Maughan BL, Zhang J, Pachynski RK, Bryce AH, Lin DW, Quinn DI, Lerner SP, Thompson IM, Dorff TB, Lara PN, **Agarwal N**. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. **European Urology Oncology**. 2024. PMID: 38523017.
262. Appleman LJ, Kim SE, Harris WB, Pal SK, Pins MR, Kolesar J, **Agarwal N**, Parikh RA, Vaena DA, Ryan CW, Hashmi M, Costello BA, Cella D, Dutcher JP, DiPaola RS, Haas NB, Wagner LI, Carducci MA. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. **Journal of Clinical Oncology**. 2024. PMID: 38531002.
263. Gebrael G, Hage Chehade C, Sayegh N, Tripathi N, Chigarira B, Goel D, Nordblad B, McFarland TR, Narang A, Srivastava A, Tandar C, Dal E, Jo Y, Galarza Fortuna G, Mathew Thomas V, Sahu KK, Li H, Maughan BL, Swami U, **Agarwal N**. Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting. **The Prostate**. 2024. PMID: 38561317.
264. Gebrael G, Jo Y, Mathew Thomas V, Li H, Sayegh N, Tripathi N, Srivastava A, Nordblad B, Dal E, Narang A, Brundage J, Campbell P, Galarza Fortuna G, Hage Chehade C, Maughan BL, **Agarwal N\***, Swami U\* (\*co-corresponding author). Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor. **Cancer**. 2024. PMID: 38564301.
265. George DJ, **Agarwal N**, Ramaswamy K, Klaassen Z, Bitting RL, Russell D, Sandin R, Emir B, Yang H, Song W, Lin Y, Hong A, Gao W, Freedland SJ. Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer. **Prostate Cancer and Prostatic Diseases**. 2024. PMID: 38565911.
266. Gebrael G, Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, Tripathi N, Castro D, Mercier B, Barragan-Carrillo R, Li H, Chehrrazi-Raffle A, Swami U, Tripathi A, **Agarwal N**, Maughan BL, Pal SK. Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations. **European Urology Focus**. 2024. PMID: 38580524.
267. Pal SK, Tran B, Haanen JBAG, Hurwitz ME, Sacher A, Tannir NM, Budde LE, Harrison SJ, Klobuch S, Patel SS, Meza L, Dequeant ML, Ma A, He QA, Williams LM, Keegan A, Gurary EB, Dar H, Karnik S, Guo C, Heath H, Yuen RR, Morrow PK, **Agarwal N**, Srour SA. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. **Cancer Discovery**. 2024. PMID: 38583184.
268. Saad E, Gebrael G, Semaan K, Eid M, Saliby RM, Labaki C, Sayegh N, Wells JC, Takemura K, Ernst MS, Lemelin A, Basappa NS, Wood LA, Powles T, Ernst DS, Lalani AA, **Agarwal N**, Xie W, Heng DYC, Choueiri TK. Impact of smoking status on clinical

- outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens. **The Oncologist**. **2024**. PMID: 38630540.
269. Mathew Thomas V, Jo Y, Tripathi N, Roy S, Chigarira B, Narang A, Gebrael G, Hage Chehade C, Sayegh N, Galarza Fortuna G, Ji R, Campbell P, Li H, **Agarwal N**, Gupta S, Swami U. Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US. **JAMA Network Open**. **2024**. PMID: 38696168.
270. Miller CD, Lozada JR, Zorko NA, Elliott A, Makovec A, Radovich M, Heath EI, **Agarwal N**, Mckay RR, Garje R, Bastos BR, Hoon DSB, Orme JJ, Sartor O, VanderWalde A, Nabhan C, Sledge G, Shenderov E, Dehm SM, Lou E, Miller JS, Hwang JH, Antonarakis ES. Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies. **Cancer Research Communications**. **2024**. PMID: 38709075.
271. Mathew Thomas V, Sayegh N, Chigarira B, Gebrael G, Tripathi N, Nussenzveig R, Jo Y, Dal E, Galarza Fortuna G, Li H, Sahu KK, Srivastava A, Maughan BL, **Agarwal N**, Swami U. Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy. **European Urology Oncology**. **2024**. PMID: 38735779.
272. Mathew Thomas V, Chigarira B, Gebrael G, Sayegh N, Tripathi N, Nussenzveig R, Jo Y, Dal E, Galarza Fortuna G, Li H, Sahu KK, Srivastava A, Maughan BL, **Agarwal N**, Swami U. Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMI. **JCO Precision Oncology**. **2024**. PMID: 38781543.
273. Lara PN Jr, Tangen C, Heath EI, Gulati S, Stein MN, Meng M, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, **Agarwal N**, Uzzo R, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Lerner S, Thompson IM Jr, Ryan CW. Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. **European Urology**. **2024**. PMID: 38811313.
274. Tannir NM, Formiga MN, Penkov K, Kislov N, Vasiliev A, Gunnar Skare N, Hong W, Dai S, Tang L, Qureshi A, Zalevsky J, Tagliaferri MA, George D, **Agarwal N\***, Pal S\* (\*equal contribution). Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09). **Journal of Clinical Oncology**. **2024**. PMID: 38838287.
275. Lowentritt BH, Du S, Rossi C, Muser E, Khilfeh I, Kinkead F, Korsiak J, Lefebvre P, Pilon D, **Agarwal N**. Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide. **Future Oncology**. **2024**. PMID: 38861305.
276. Tripathi N, Gebrael G, Chigarira B, Sahu KK, Balasubramanian I, Caparas C, Mathew Thomas V, Cohan JN, Pelletier K, Maughan BL, **Agarwal N**, Swami U, Gupta S. Treatment Patterns and Outcomes by Age in Metastatic Urinary Tract Cancer: A Retrospective Tertiary Cancer Center Analysis. **Cancers (Basel)**. **2024**. PMID: 38893262.
277. Takemura K, Yuasa T, Lemelin A, Ferrier E, Wells JC, Saad E, Saliby RM, Basappa NS, Wood LA, Jude E, Pal SK, Donskov F, Beuselinck B, Szabados B, Powles T, McKay RR, Gebrael G, **Agarwal N**, Choueiri TK, Heng DY. Prognostic significance of

- absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium. **ESMO Open**. 2024. PMID: 38901174.
278. Merseburger AS, **Agarwal N**, Bjartell A, Uemura H, Soto AJ, Bhaumik A, Böhm J, Tran N, Krochmann N, Nematian-Samani M, Mundle SD, Brookman-May SD, Lopez-Gitlitz A, McCarthy SA, Chi K, Chowdhury S. Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy. **BJU International**. 2024. PMID: 38940282.
279. Gebrael G, Jo Y, Swami U, Plets M, Hage Chehade C, Narang A, Gupta S, Myint ZW, Sayegh N, Tangen CM, Hussain M, Dorff T, Lara PN Jr, Lerner SP, Thompson I, **Agarwal N**. Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. **JAMA Network Open**. 2024. PMID: 38980676.
280. Hage Chehade C, Jo Y, Gebrael G, Tripathi N, Sayegh N, Chigarira B, Mathew Thomas V, Galarza Fortuna G, Narang A, Campbell P, Gupta S, Maughan BL, Roy S, **Agarwal N\***, Swami U\* (**\*co-corresponding author**). Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers. **JAMA Network Open**. 2024. PMID: 39023888.
281. Roy S, Sun Y, Chi KN, Ong M, Malone S, Wallis CJD, Kishan AU, Malone J, Swami U, Gebrael G, Brown JR, Jia AY, Morgan SC, Saad F, Chowdhury S, **Agarwal N**, Spratt DE. Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of TITAN Trial. **The Journal of Urology**. 2024. PMID: 39058790.
282. Fortuna GG, Chigarira B, Thomas VM, Sahu KK, Kumar SA, Tripathi N, Sayegh N, **Agarwal N**, Swami U, Maughan BL, Li H. Clinical, Genomic, and Transcriptomic Characteristics of Patients with Metastatic Renal Cell Carcinoma Who Developed Thromboembolic Events. **Journal of Kidney Cancer and VHL**. 2024. PMID: 39100549.
283. Nain P, Stabellini N, Makram OM, Rast J, Yerraguntla S, Gopu G, Bhave A, Seth L, Patel V, Jiang S, Malik S, Shetewi A, Montero AJ, Cullen J, **Agarwal N**, Wang X, Ky B, Baldassarre LA, Weintraub NL, Harris RA, Guha A. Adverse Social Determinants of Health Elevate Uncontrolled Hypertension Risk: A Cardio-Oncology Prospective Cohort Study. **JNCI Cancer Spectrum**. 2024. PMID: 39115393.
284. Hussain M, Kocherginsky M, **Agarwal N**, Adra N, Zhang J, Paller CJ, Picus J, Reichert ZR, Szmulewitz RZ, Tagawa ST, Kuzel TM, Bazzi LA, Daignault-Newton S, Whang YE, Dreicer R, Stephenson RD, Rettig MB, Shevrin D, Gerke T, Chinnaiyan AM, Antonarakis ES. Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). **Clinical Cancer Research**. 2024. PMID: 39115414.
285. **Agarwal N**, Brugarolas J, Ghatalia P, George S, Haanen JB, Gurney H, Ravilla R, Van der Veldt A, Beuselinck B, Pokataev I, Suelmann BBM, Tuthill MH, Vaena D, Zagouri F, Wu J, Perini RF, Liu Y, Merchan J, Atkins MB. Randomized phase 2 dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. **Annals of Oncology**. 2024. PMID: 39233312.

286. Triner D, Graf RP, Madison RW, Gjoerup O, Tukachinsky H, Ross JS, Quintanilha JCF, Li G, Cheng HH, Pritchard CC, Zurita AJ, Qin Q, Zhang T, **Agarwal N**, Reichert ZR, Mateo J, Cieslik M, Morgan TM. Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing. **ESMO Open**. **2024**. PMID: 39255537.
287. Petrylak DP, Tagawa ST, Jain RK, Bupathi M, Balar A, Kalebasty AR, George S, Palmboos P, Nordquist L, Davis N, Ramamurthy C, Sternberg CN, Loriot Y, **Agarwal N**, Park C, Tonelli J, Vance M, Zhou H, Grivas P. TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy. **Journal of Clinical Oncology**. **2024**. PMID: 39186707.
288. Bakaloudi DR, Talukder R, Makrakis D, Diamantopoulos L, Enright T, Leary JB, Patgunarajah U, Thomas VM, Swami U, **Agarwal N**, Jindal T, Koshkin VS, Brown JR, Barata P, Murgic J, Miletic M, Johnson J, Zakharia Y, Hui G, Drakaki A, Duran I, Buznego LA, Barrera RM, Castañeda DM, Rey-Cárdenas M, Castellano D, Nguyen CB, Park JJ, Alva A, McKay RR, Stewart TF, Epstein IB, Bellmunt J, Wright JL, Gupta S, Grivas P, Khaki AR. Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor. **Clinical Genitourinary Cancer**. **2024**. PMID: 39241315.
289. Roy S, Saad F, Sun Y, Malone S, Spratt DE, Kishan AU, Wallis CJD, Jia AY, Mohamad O, Swami U, Ong M, **Agarwal N**, Chowdhury S, Morgan SC. Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial. **European Journal of Cancer**. **2024**. PMID: 39243730.
290. Narang A, Gebrael G, Jo Y, Thomas VM, Li H, Fortuna GG, Sayegh N, Tandar C, Tripathi N, Chigarira B, Srivastava A, Hage Chehade C, Nordblad B, Maughan BL, **Agarwal N\***, Swami U\* (\***co-corresponding author**). Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations. **Kidney Cancer**. **2024**. PMID: 39263256.
291. Dal E, Srivastava A, Chigarira B, Hage Chehade C, Matthew Thomas V, Galarza Fortuna GM, Garg D, Ji R, Gebrael G, **Agarwal N**, Swami U, Li H. Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma. **Diagnostics (Basel)**. **2024**. PMID: 39272684.
292. Abdallah N, Elliott A, Smith N, Stanford SM, **Agarwal N**, Bagrodia A, Garje R, Bottini N, McKay RR. Dissecting the Significance of Acid Phosphatase 1 Gene Alterations in Prostate Cancer. **JCO Precision Oncology**. **2024**. PMID: 39348661.
293. Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski JK, Ingles S, Triche TJ, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN Jr, Hussain MHA, Quinn DI, Dorff TB, Lerner SP, Thompson I Jr, **Agarwal N**. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. **JAMA Network Open**. **2024**. PMID: 39374015.
294. Roy S, Malone S, Wing K, Chowdhury S, Kishan AU, Sun Y, Wallis CJD, Mohamad O, Jia AY, Swami U, Zaorsky NG, Morgan SC, Ong M, **Agarwal N**, Spratt DE, Small EJ,

- Saad F. Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial. **JAMA Network Open**. 2024. PMID: 39405060.
295. Azad AA, Fizazi K, Matsubara N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Lin X, DeAnnuntis L, Di Santo N, Zielinski MA, **Agarwal N**. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study. **European Journal of Cancer**. 2024. PMID: 39486165.
296. Swami U, Jo Y, Narang A, Plets M, Hage Chehade C, Gebrael G, Gupta S, Myint Z, Tangen C, Lara PN Jr, Thompson IM Jr, Hussain MHA, Dorff TB, Lerner SP, **Agarwal N**. Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216. **European Urology Oncology**. 2024. PMID: 39521639.
297. Campbell P, Gebrael G, Narang A, Chehade CH, Thomas VM, Galarza Fortuna G, Sayegh N, Tripathi N, Tandar C, Dal E, Li H, Swami U, **Agarwal N**, Maughan BL. Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix. **Therapeutic Advances in Urology**. 2024. PMID: 39524157.
298. **Agarwal N**, George DJ, Klaassen Z, Sandin R, Butcher J, Ribbands A, Gillespie-Akar L, Emir B, Russell D, Hong A, Ramaswamy K, Freedland SJ. Physician Reasons for or Against Treatment Intensification in Patients With Metastatic Prostate Cancer. **JAMA Network Open**. 2024. PMID: 39652349.
299. Ye DW, Uemura H, Chung BH, Suzuki H, Mundle S, Bhaumik A, Singh A, Chowdhury S, **Agarwal N**, Chi KN, Huang J. Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis. **International Journal of Urology**. 2024. PMID: 39648954.
300. Sayegh N, Jo Y, Gebrael G, Tripathi N, Chigarira B, Srivastava A, Nordblad B, Dal E, Hage Chehade C, Mahlow J, Maughan BL, Gupta S, **Agarwal N**, Swami U. Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma. **Clinical Genitourinary Cancer**. 2024. PMID: 39721833.
301. Talukder R, Bakaloudi DR, Makrakis D, Diamantopoulos LN, Enright T, Leary JB, Raychaudhuri R, Tripathi N, **Agarwal N**, Jindal T, Brown JR, Zakharia Y, Rey-Cárdenas M, Castellano D, Nguyen CB, Alva A, Zakopoulou R, Bamias A, Barrera RM, Marmolejo D, Drakaki A, Pinato DJ, Korolewicz J, Buznego LA, Duran I, Carballeira CC, McKay RR, Stewart TF, Gupta S, Barata P, Yu EY, Koshkin VS, Khaki AR, Grivas P. Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma. **Clin Genitourin Cancer**. 2025. PMID: 39798390.
302. Naqvi SAA, Riaz IB, Bibi A, Khan MA, Imran M, Khakwani KZR, Raina A, Anjum MU, Cobran EK, Warner JL, Hussain SA, Singh P, Childs DS, Baca SC, Orme JJ, Mateo J, **Agarwal N**, Gillessen S, Murad MH, Sartor O, Bryce AH. Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis. **Eur Urol**. 2025. PMID: 39848867.

303. Maiorano BA, Catalano M, Mercinelli C, Cigliola A, Tateo V, **Agarwal N**, Gupta S, Roviello G, Necchi A. Incidence and Risk of Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Safety Meta-analysis. **Eur Urol Open Sci.** 2025. PMID: 39882554.
304. Stabellini N, Makram OM, Kunhiraman HH, Daoud H, Shanahan J, Montero AJ, Blumenthal RS, Aggarwal C, Swami U, Virani SS, Noronha V, **Agarwal N**, Dent S, Guha A. A novel machine learning-based cancer-specific cardiovascular disease risk score among patients with breast, colorectal, or lung cancer. **JNCI Cancer Spectr.** 2025. PMID: 39883570.
305. Gebrael G, Sayegh N, Hage Chehade C, Jo Y, Narang A, Chigarira B, Tripathi N, Srivastava A, Tandar C, Williams JF, Garg D, Ji R, Maughan BL, Swami U, **Agarwal N**. Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy. **Prostate Cancer Prostatic Dis.** 2025. PMID: 39885371.
306. Gandara DR, **Agarwal N**, Gupta S, Klempner SJ, Andrews MC, Mahipal A, Subbiah V, Eskander RN, Carbone DP, Riess JW, Sammons S, Snider J, Bouzit L, Cho-Phan C, Price M, Li G, Quintanilha JCF, Huang RSP, Ross JS, Fabrizio D, Oxnard GR, Graf RP. Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types. **J Immunother Cancer.** 2025. PMID: 39915003.
307. Tward J, Lloyd S, Johnson S, Dechet C, Nei BO, Maughan B, Swami U, Gupta S, Sanchez A, Kokeny K, **Agarwal N**. A Phase 2 Trial of Radium223 and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR Study. **Int J Radiat Oncol Biol Phys.** 2025. PMID: 39922320.
308. Pal SK, Lorient Y, Necchi A, Singh P, Castellano D, Pagliaro L, Suarez C, McGregor BA, Vaishampayan UN, Hauke RJ, Powles T, Van Herpen CML, Courtney KD, Dreicer R, Sudhagoni R, Schwickart M, Andrianova S, **Agarwal N**. COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts. **J Clin Oncol.** 2025. PMID: 39965176.
309. Hariri D, Pavlick D, Spiess P, Li R, Kamat A, Grivas P, **Agarwal N**, Gupta S, Necchi A, Bratslavsky G, Basnet A, Jacob J, Ross J, Kravtsov O. Primary sarcomas of the bladder and prostate: A genomic landscape study. **Pathol Res Pract.** 2025. PMID: 39965403.
310. Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, O'Neil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, **Agarwal N**, Gupta S. Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). **J Immunother Cancer.** 2025. PMID: 40102029.
311. Ozay ZI, Jo Y, Galarza Fortuna G, Hage Chehade C, Gebrael G, Ostrowski M, Sayegh N, Anderson E, Jaime-Casas S, Zugman M, Mathew Thomas V, Maughan BL, **Agarwal N**, Pal SK, Swami U. Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US. **JAMA Netw Open.** 2025. PMID: 40111367.
312. Matsubara N, Azad AA, **Agarwal N**, Saad F, Giorgi UD, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Cislo P, Chang J, Healy CG, Niyazov A, Fizazi K. Patient-reported outcomes in men with metastatic castration-resistant prostate cancer receiving first-line talazoparib plus enzalutamide in

- the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. **Lancet Oncology**. **2025**. PMID: 40179906.
313. Fay AP, Fizazi K, Matsubara N, Azad AA, Saad F, Giorgi UD, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Cislo P, Chang J, Healy CG, Niyazov A, **Agarwal N**. Patient-reported outcomes in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations treated with talazoparib plus enzalutamide: results from the randomised TALAPRO-2 trial. **Lancet Oncology**. **2025**. PMID: 40179907.
  314. Kellen S, Makovec A, Miller CD, Nazari SS, Elliott A, Deacon A, John E, Vobugari N, **Agarwal N**, McKay RR, Barata PC, Ryan CJ, Sharifi N, Hwang J, Antonarakis ES. The Influence of the Germline HSD3B1 Adrenal-Permissive Allele (c.1100 C) on the Somatic Alteration Landscape, the Transcriptome, and Immune Cell Infiltration in Prostate Cancer. **Cancers (Basel)**. **2025**. PMID: 40282446.
  315. Jain RK, Swami U, Bilen MA, Gebrael G, Boucher KM, Braun E, Brown JT, Chahoud J, Gupta S, **Agarwal N**, Sonpavde G, Maughan BL. Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial. **Eur Urol Oncol**. **2025**. PMID: 40307092.
  316. Ostrowski M, Jo Y, Gebrael G, Chehade CH, Ozay ZI, Nordblad B, Srivastava A, Garg D, Ji R, Fortuna GG, Thomas VM, Chigarira B, Anderson E, **Agarwal N**, Maughan BL, Swami U. First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma. **J Kidney Cancer VHL**. **2025**. PMID: 40302852.
  317. **Agarwal N**, Azad AA, Carles J, Matsubara N, Oudard S, Saad F, Merseburger AS, Soares A, McGregor BA, Zurawski B, Tsiatas M, North S, Bondarenko I, Alfie M, Bournakis E, Antonuzzo L, Evilevitch L, Dong H, Simmons A, Wang F, Ferraldeschi R, Nandoskar P, Pal SK. Cabozantinib plus atezolizumab in metastatic prostate cancer: final analyses from a phase 3 open-label, randomised trial (CONTACT-02). **Lancet Oncology**. **2025**. PMID: 40523369.
  318. Hage Chehade C, Graf RP, Ozay ZI, Gebrael G, Sayegh N, Li G, Maughan BL, Antonarakis ES, McKay RR, **Agarwal N\***, Swami U. (**\*co-corresponding author**). Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer. *Clinical Cancer Research*. **2025**. PMID: 40522300
  319. Fizazi K\*, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Kalac M, Laird DA, Kennedy D, **Agarwal N\*** (**\*equal contribution**). Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled phase 3 TALAPRO-2 trial. **The Lancet**. **2025**. In press.
  320. **Agarwal N\***, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Saad F, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Kalac M, Kennedy D, Fizazi K\* (**\*equal contribution**). Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. **The Lancet**. **2025**. In press.

## B. Review Articles (Total: 73)

1. Agarwal N, Spahr JE, Werner TL, Newton DL, Rodgers GM. Acquired amegakaryocytic thrombocytopenic purpura. **American Journal of Hematology**. 2006. PMID: 16432869.
2. Agarwal N, Werner TL, Carney HM, Rodgers GM. Management of cancer associated thrombotic microangiopathy: What is the right approach? **American Journal of Hematology**. 2007. PMID: 17034030.
3. Agarwal N, Gordeuk VR, Prchal JT. Genetic Mechanisms Underlying Regulation of Hemoglobin Mass. **Advances in Experimental Medicine and Biology**. 2007. PMID: 18269198.
4. Agarwal N, Prchal JT. Erythropoietic Agents and the Elderly. **Seminars in Hematology** 2008. PMID: 18809098.
5. Agarwal N, Hussain M. Management of Bladder Cancer: Current and Emerging Strategies. **Drugs**. 2009. PMID: 19537835.
6. Agarwal N, Batten J. Optimal Treatment Options in the Post Orchiectomy Management of Clinical Stage 1 Seminoma. **Oncology (Williston Park)**. 2009. PMID: 19777761.
7. Agarwal N, Prchal JT. Anemia of Chronic Disease (Anemia of Inflammation). **Acta Haematologica**. 2009. PMID: 19907147.
8. Agarwal N, Hutson TE, Vogelzang NJ, Sonpavde G. Abiraterone acetate: a promising drug for the treatment of castration resistant prostate cancer. **Future Oncology**. 2010. PMID: 20465382.
9. Agarwal N, Sonpavde G, Sartor O. Cabazitaxel in the treatment of castration refractory prostate cancer. **Future Oncology**. 2011. PMID: 21174534.
10. Agarwal N, Vogelzang NJ. Secondary hormonal manipulations in the treatment of castration refractory prostate cancer. **BJU International**. 2011. PMID: 21410863.
11. Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW. Immunotherapy for the treatment of prostate cancer. **Expert Opinion in Biological Therapy**. 2011. PMID: 21675925.
12. Agarwal N, Sonpavde G, Sternberg CN. Novel Molecular Targets for the Therapy of Castration- Resistant Prostate Cancer. **European Urology**. 2012. PMID: 22209376.
13. Agarwal N, Padmanbh S, Vogelzang NJ. Development of novel immune interventions for prostate cancer. **Clinical Genitourinary Cancer**. 2012. PMID: 22409862.
14. Zhang TY\*, Agarwal N\*, Sonpavde G, DiLorenzo G, Bellmunt J, Vogelzang NJ (\***equal contribution**). Management of castrate resistant prostate cancer - recent advance and optimal sequence of treatments. **Current Urology Report**. 2013. PMID: 23559076.
15. Patel JC, Maughan BL, Agarwal AM, Batten JM, Zhang TY, Agarwal N. Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer. **Prostate Cancer**. 2013. PMID: 23819055.
16. Agarwal N, Hussain M. Management of newly diagnosed metastatic prostate cancer. **Hematology/Oncology Clinics of North America**. 2013. PMID: 24188260.
17. Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J. New Agents for Prostate Cancer. **Annals of Oncology**. 2014. PMID: 24658665.
18. Reese Z, Straubhar A, Pal SK, Agarwal N. Ipilimumab in prostate cancer. **Future Oncology**. 2015. PMID: 25572782.
19. Singh P, Agarwal N, Pal SK. Sequencing Systemic Therapies for Metastatic Kidney Cancer. **Current Treatment Options in Oncology**. 2015. PMID: 25648540.

20. Gupta S, Gill D, Pal SK, **Agarwal N**. Activin receptor inhibitors-dalantercept. **Current Oncology Reports**. 2015. PMID: 25708802.
21. Singh P, Pal SK, Alex A, **Agarwal N**. Development of PROSTVAC immunotherapy in prostate cancer. **Future Oncology**. 2015. PMID: 26235179.
22. **Agarwal N**, Sonpavde G, Choueiri TK, Pal SK. Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine. **European Urology**. 2016. PMID: 26873842.
23. Alex AB, Pal SK, **Agarwal N**. CYP17 inhibitors in prostate cancer: latest evidence and clinical potential. **Therapeutic Advances in Medical Oncology**. 2016. PMID: 27482286.
24. Gill D, Hahn AW, Sonpavde G, **Agarwal N**. Immunotherapy of advanced renal cell carcinoma: Current and future therapies. **Human Vaccines Immunotherapeutics**. 2016. PMID: 27494417.
25. Gupta S, Gill D, Poole A, **Agarwal N**. Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions. **Cancers**. 2017. PMID: 28134806.
26. Gill DM, **Agarwal N**, Vaishampayan U. Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma. **American Society of Clinical Oncology (ASCO) Educational Book**. 2017. PMID: 28561652.
27. Hahn AW, Gill DM, Pal SK, **Agarwal N**. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. **Immunotherapy**. 2017. PMID: 28653573.
28. Hahn AW, Hale P, Rathi N, **Agarwal N**. Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer. **Current Opinion in Urology**. 2017. PMID: 28816716.
29. Hahn AW, Gill DM, **Agarwal N**, Maughan BL. PD-1 checkpoint inhibition: Toxicities and management. **Urologic Oncology**. 2017. PMID: 28889921.
30. Gill DM, **Agarwal N**. Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers. **Urologic Oncology**. 2017. PMID: 29054496.
31. Corn PG, **Agarwal N**, Araujo JC, Sonpavde G. Taxane-based Combination Therapies for Metastatic Prostate Cancer. **European Urology Focus**. 2017, Dec 20. PMID: 29275145.
32. Zhen JT, Syed J, Nguyen KA, Leapman MS, **Agarwal N**, Brierley K, Llor X, Hofstatter E, Shuch B. Genetic testing for hereditary prostate cancer: Current status and limitations. **Cancer**. 2018. PMID: 29669169.
33. Dorff TB, **Agarwal N**. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer. **Asian Journal of Andrology**. 2018. PMID: 29553053.
34. Hahn AW, Higano CS, Taplin ME, Ryan CJ, **Agarwal N**. Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. **American Society of Clinical Oncology (ASCO) Educational Book**. 2018. PMID: 30231388.
35. Sirohi D, Smith SC, **Agarwal N**, Maughan BL. Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. **Research and Reports in Urology**. 2018. PMID: 30510921.
36. Esther J, Maughan BL, Anderson N, **Agarwal N**, Hahn AW. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. **Current Treatment Options in Oncology**. 2019. PMID: 30741354.
37. Esther J, Hale P, Hahn AW, **Agarwal N\***, Maughan BL\* (\*co-corresponding author). Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients:

- The Role of TKIs and Immune Checkpoint Inhibitors. **Drugs & Aging**. 2019. PMID: 30784023.
38. Hahn AW, Sirohi D, **Agarwal N**. The Role of PD-L1 Testing in Advanced Genitourinary Malignancies (Epub ahead of print). **European Urology Focus**. 2019. PMID: 30872123.
  39. Nandagopal L, Sonpavde GP, **Agarwal N**. Investigational MET inhibitors to treat Renal cell carcinoma. **Expert Opinion on Investigational Drugs**. 2019. PMID: 31554440.
  40. Johnson E, Nussenzweig R, **Agarwal N\***, Swami U\* (**\*co-corresponding author**). Germline variants and response to systemic therapy in advanced prostate cancer. **Pharmacogenomics**. 2020. PMID: 31849283.
  41. Barata P, Swami U, **Agarwal N**. The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy. **Expert Review of Anticancer Therapy**. 2020. PMID: 32068456.
  42. Bhowmick NA, Oft J, Dorff T, Pal S, **Agarwal N**, Figlin RA, Posadas EM, Freedland SJ, Gong J. COVID-19 and androgen-targeted therapy for prostate cancer patients. **Endocrine-Related Cancer**. 2020. PMID: 32508311.
  43. Swami U, McFarland TR, Nussenzweig R, **Agarwal N**. Advanced Prostate Cancer: Treatment Advances and Future Directions. **Trends in Cancer**. 2020. PMID: 32534790.
  44. Rathi N, Maughan BL, **Agarwal N\***, Swami U\* (**\*co-corresponding author**). Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma. **Cancer Management and Research**. 2020. PMID: 32547210.
  45. Tripathi A, Balakrishna P, **Agarwal N**. PARP inhibitors in castration-resistant prostate cancer. **Cancer Treatment and Research Communications**. 2020. PMID: 32745972.
  46. Swami U, **Agarwal N**. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer. **Cancer Treatment and Research Communications**. 2020. PMID: 32822968.
  47. Rathi N, McFarland TR, Nussenzweig R, **Agarwal N**, Swami U. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. **Drugs**. 2020. PMID: 33369720.
  48. Mundle R, Afenya E, **Agarwal N**. The effectiveness of psychological intervention for depression, anxiety, and distress in prostate cancer: a systematic review of literature. **Prostate Cancer and Prostatic Diseases**. 2021. PMID: 33750905.
  49. Grivas P, **Agarwal N**, Pal S, Kalebasty AR, Sridhar SS, Smith J, Devgan G, Sternberg CN, Bellmunt. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. **Cancer Treatment Reviews**. 2021. PMID: 33839438.
  50. Venkatachalam S, McFarland TR, **Agarwal N**, Swami U. Immune Checkpoint Inhibitors in Prostate Cancer. **Cancers (Basel)**. 2021. PMID: 34063238.
  51. McFarland TR, Kessel A, Swami U, **Agarwal N**. Development of PARP inhibitor combinations for castration-resistant prostate cancer unselected for homologous recombination repair mutations. **American Journal of Translational Research**. 2021. PMID: 34377227.
  52. Sayegh N, Swami U, **Agarwal N**. Recent Advances in the Management of Metastatic Prostate Cancer. **JCO Oncology Practice**. 2021. PMID: 34473525.

53. Guha A, Gong Y, DeRemer D, Owusu-Guha J, Dent SF, Cheng RK, Weintraub NL, **Agarwal N**, Fradley MG. Cardiometabolic consequences of targeted anticancer therapies. **Journal of Cardiovascular Pharmacology**. 2021. PMID: 34654781.
54. Carril-Ajuria L, Martin-Soberón MC, de Velasco G, **Agarwal N**, Castellano D. Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review. **Journal of Cancer Research and Clinical Oncology**. 2022. PMID: 35064817.
55. Mathew Thomas V, Tripathi N, **Agarwal N**, Swami U. Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. **Expert Review of Anticancer Therapy**. 2022. PMID: 35249433.
56. Weiner AB, Siebert AL, Fenton SE, Abida W, **Agarwal N**, Davis ID, Dorff TB, Gleave M, James ND, Poon DMC, Suzuki H, Sweeney CJ. First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature. **European Urology Oncology**. 2022. PMID: 35641398.
57. Sahu KK, Tripathi N, **Agarwal N**, Swami U. Relugolix in the management of prostate cancer. **Expert Review of Anticancer Therapy**. 2022. PMID: 35866612.
58. Sayegh N, Tripathi N, **Agarwal N**, Swami U. Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma. **OncoTargets and Therapy**. 2022. PMID: 36186154.
59. Sayegh N, Yirerong J, **Agarwal N**, Addison D, Fradley M, Cortes J, Weintraub NL, Sayed N, Raval G, Guha A. Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors. **Current Cardiology Reports**. 2023. PMID: 36795308.
60. Gebrael G, Sahu KK, **Agarwal N**, Maughan BL. Update on combined immunotherapy for the treatment of advanced renal cell carcinoma. **Human Vaccines Immunotherapeutics**. 2023. PMID: 37062953.
61. Hamid AA, Sayegh N, Tombal B, Hussain M, Sweeney CJ, Graff JN, **Agarwal N**. Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment. **American Society of Clinical Oncology (ASCO) Educational Book**. 2023. PMID: 37220335.
62. Gebrael G, Fortuna GG, Sayegh N, Swami U, **Agarwal N**. Advances in the treatment of metastatic prostate cancer. **Trends in Cancer**. 2023. PMID: 37442702.
63. **Agarwal N**, Zhang T, Efstathiou E, Sayegh N, Engelsberg A, Saad F, Fizazi K. The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer. **European Journal of Cancer**. 2023. PMID: 37672815.
64. McKay RR, Morgans AK, Shore ND, Dunshee C, Devgan G, **Agarwal N**. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States. **Cancer Treatment Reviews**. 2024. PMID: 38613872.
65. Tan MC, Stabellini N, Tan JY, Thong JY, Hedrick C, Moore JX, Cullen J, Hines A, Sutton A, Sheppard V, **Agarwal N**, Guha A. Reducing racial and ethnic disparities in cardiovascular outcomes among cancer survivors. **Current Oncology Reports**. 2024. PMID: 39002054.
66. Narang A, Hage Chehade C, Ozay ZI, Nordblad B, Swami U, **Agarwal N**. Talazoparib for the treatment of prostate cancer. **Expert Opinion on Pharmacotherapy**. 2024. PMID: 39210559.

67. Francini E, **Agarwal N**, Castro E, Cheng HH, Chi KN, Clarke N, Mateo J, Rathkopf D, Saad F, Tombal B. Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review. **European Urology**. 2024. PMID: 39306478.
68. Shore N, Carles J, McDermott R, **Agarwal N**, Tombal B. Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer. **Frontiers in Medicine (Lausanne)**. 2024. PMID: 39526247.
69. Chehade CH, Gebrael G, Sayegh N, Ozay ZI, Narang A, Crispino T, Golan T, Litton JK, Swami U, Moore KN, **Agarwal N**. A pan-tumor review of the role of poly (adenosine diphosphate ribose) polymerase inhibitors. **CA Cancer J Clin**. 2025. PMID: 39791278.
70. Azad AA, Kostos L, **Agarwal N**, Attard G, Davis ID, Dorff T, Gillissen S, Parker C, Smith MR, Sweeney CJ, Tombal B, Fizazi K. Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer. **Eur Urol**. 2025. PMID: 39947976.
71. Chehade CH, Ozay ZI, Ostrowski M, Mercinelli C, Gebrael G, Sayegh N, Swami U, Azad A, Antonarakis ES, **Agarwal N**. T-cell Engagers in Prostate Cancer. **Eur Urol**. 2025. PMID: 40074645.
72. Naqvi SAA, Anjum MU, Bibi A, Khan MA, Khakwani KZR, He H, Imran M, Kazmi SZ, Raina A, Cobran EK, Bryan Rumble R, Oliver TK, **Agarwal N**, Zakharia Y, Taplin ME, Sartor O, Singh P, Orme JJ, Childs DS, Parikh RA, Garje R, Murad MH, Bryce AH, Riaz IB. Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review. **medRxiv**. 2025. PMID: 40321256.
73. Grewal K, Dorff TB, Mukhida SS, **Agarwal N**, Hahn AW. Advances in Targeted Therapy for Metastatic Prostate Cancer. **Curr Treat Options Oncol**. 2025. PMID: 40299225.

### C. Practice Guidelines, Expert Consensus, and Position Statement Articles (Total: 36)

1. Motzer RJ, **Agarwal N**, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. **Journal of National Comprehensive Cancer Network (JNCCN)**. 2009. PMID: 19555584.
2. Motzer RJ, **Agarwal N**, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. **Journal of National Comprehensive Cancer Network (JNCCN)**. 2009. PMID: 19555582.
3. Motzer RJ, **Agarwal N**, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB. Kidney Cancer. **Journal of National Comprehensive Cancer Network**. 2011. PMID: 21917622.
4. Motzer RJ, **Agarwal N**, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM,

- Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB. Testicular Cancer. **Journal of National Comprehensive Cancer Network (JNCCN)**. 2012. PMID: 22491049.
5. Clark PE, **Agarwal N**, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. (2013). Bladder Cancer. **Journal of the National Comprehensive Cancer Network**. 2013. PMID: 23584347.
  6. Clark PE, Spiess PE, **Agarwal N**, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile Cancer. **Journal of the National Comprehensive Cancer Network (JNCCN)**. 2013. PMID: 23667209.
  7. Motzer RJ, Jonasch E, **Agarwal N**, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam EL, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson DM, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer M, Kumar R. Kidney Cancer, Version 2.2014. Featured Updates to the NCCN Guidelines: Non Clear Cell Variant Kidney Cancer. **Journal of the National Comprehensive Cancer Network (JNCCN)**. 2014. PMID: 24586079.
  8. Motzer RJ, Jonasch E, **Agarwal N**, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Kidney cancer, version 3.2015. **Journal of the National Comprehensive Cancer Network (JNCCN)**. 2015. PMID: 25691606.
  9. Motzer RJ, Jonasch E, **Agarwal N**, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Testicular Cancer, Version 2.2015. **Journal of National Comprehensive Cancer Network (JNCCN)**. 2015. PMID: 26085393.
  10. Pal SK, **Agarwal N**, Boorjian SA, Hahn NM, Siefker-Radtke AO, Clarke PE, Plimack ER. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. **Journal of Clinical Oncology**. 2016. PMID: 27458279.
  11. Clark PE, Spiess PE, **Agarwal N**, Bangs R, Boorjian SA, Buyyounouski MK, Efsthathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. **Journal of National Comprehensive Cancer Network (JNCCN)**. 2016. PMID: 27697976.
  12. Motzer RJ, Jonasch E, **Agarwal N**, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson

- MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. **Journal of the National Comprehensive Cancer Network (JNCCN)**. **2017**. PMID: 28596261.
13. Spiess PE, **Agarwal N**, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. **Journal of National Comprehensive Cancer Network (JNCCN)**. **2017**. PMID: 28982750.
  14. Flaig TW, Spiess PE, **Agarwal N**, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. **Journal of National Comprehensive Cancer Network (JNCCN)**. **2018**. PMID: 30181416.
  15. Pal SK, Miller MJ, **Agarwal N**, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE. Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. **Journal of Clinical Oncology**. **2019**. PMID: 30702028.
  16. Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, **Agarwal N**, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA, CGC, Hammond LJ, Zuccarino-Catania G. NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. **Journal of the National Comprehensive Cancer Network (JNCCN)**. **2019**. PMID: 31693980.
  17. Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, **Agarwal N**, et al. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. **European Urology**. **2019**. PMID: 31753752.
  18. Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, Van Der Kwast T, Grignon DJ, Rai AJ, **Agarwal N**, Klein EA, Den RB, Beltran H. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. **Journal of Clinical Oncology**. **2019**. PMID: 31829902.
  19. Markham MJ, Wachter K, **Agarwal N**, Bertagnolli MM, Chang SM, Dale W, Diefenbach CSM, Rodriguez-Galindo C, George DJ, Gilligan TD, Harvey RD, Johnson ML, Kimple RJ, Knoll MA, LoCente N, Maki RG, Meisel JL, Meyerhardt JA, Pennell NA, Rocque

- GB, Sabel MS, Schilsky RL, Schneider BJ, Tap WD, Uzzo RG, Westin SN. Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. **Journal of Clinical Oncology**. **2020**. PMID: 32013670.
20. Flaig TW, Spiess PE, **Agarwal N**, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. **Journal of the National Comprehensive Cancer Network (JNCCN)**. **2020**. PMID: 32135513.
  21. Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, **Agarwal N**, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. **Journal of the National Comprehensive Cancer Network (JNCCN)**. **2020**. PMID: 32886895.
  22. Desai A, Gainor JF, Hegde A, Schram AM, Curigiliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, **Agarwal N**, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. **Nature Reviews Clinical Oncology**. **2021**. PMID: 33723371.
  23. Motzer RJ, Jonasch E, **Agarwal N**, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. **Journal of the National Comprehensive Cancer Network (JNCCN)**. **2022**. PMID: 34991070.
  24. Flaig TW, Spiess PE, Abern M, **Agarwal N**, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines Insights: Bladder Cancer, Version 2.2022. **Journal of the National Comprehensive Cancer Network (JNCCN)**. **2022**. PMID: 35948037.
  25. Motzer RJ, Jonasch E, **Agarwal N**, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LA. NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024. **Journal of the National Comprehensive Cancer Network (JNCCN)**. **2024**. PMID: 38394781.

26. Tateo V, Cigliola A, Mercinelli C, **Agarwal N**, Grivas P, Kamat AM, Gibb EA, Moschini M, Brausi M, Dyrskjot L, Lorient Y, Gupta S, Colecchia M, Spiess PE, Ross JS, Necchi A. Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat Panel. **Clinical Genitourinary Cancer. 2024.** PMID: 38735133.
27. Flaig TW, Spiess PE, Abern M, **Agarwal N**, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA. Bladder Cancer, Version 3.2024. **Journal of the National Comprehensive Cancer Network (JNCCN). 2024.** PMID: 38754471.
28. Crawford ED, Bryce AH, Hussain MH, **Agarwal N**, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. **JU Open Plus. 2024.** PMID: 38774466.
29. Bryce AH, Crawford ED, **Agarwal N**, Hussain MH, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. **JU Open Plus. 2024.** PMID: 38774467.
30. Shore ND, Broder MS, Barata PC, Crispino T, Fay AP, Lloyd J, Mellado B, Matsubara N, Pfanzer N, Schlack K, Sieber P, Soares A, Dalglish H, Niyazov A, Shaman S, Zielinski MA, Chang J, **Agarwal N**. Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy. **European Urology Oncology. 2024.** PMID: 38866640.
31. Chang E, Hahn NM, Lerner SP, Fallah J, Agrawal S, Kamat AM, Bhatnagar V, Svatek RS, Jaigirdar AA, Bross P, Shore N, Kates M, Sachse K, Brewer JR, O'Donnell MA, Steinberg GD, Viviano CJ, Bloomquist E, Ribal MJ, Galsky MD, Oliver R, Black PC, Al-Ahmadie H, Brothers K, Pohar K, Dinney CP, Feng Z, Downs TM, Porten SP, Smith AB, Bangs R, Psutka SP, **Agarwal N**, Amiri-Kordestani L, Suzman DL, Pazdur R, Kluetz PG, Weinstock C. Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer. **Bladder Cancer. 2023.** PMID: 38993184.
32. Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, **Agarwal N**, et al. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). **European Urology. 2024.** PMID: 39394013.

33. Oh WK\*, **Agarwal N\***, Bryce A, Barata P, Bugler C, Carlsson SV, Cornell B, Dahut W, George D, Loeb S, Montgomery B, Morris D, Mucci LA, Omlin A, Palapattu G, Riaz IB, Ryan C, Schoen MW, Washington SL 3rd, Gillessen S (**\*equal contribution, co-corresponding author**). What's in a Name? Why Words Matter in Advanced Prostate Cancer. **European Urology**. 2024. PMID: 39472202.
34. Bryce AH, **Agarwal N**, Beltran H, Hussain MH, Sartor O, Shore N, Antonarakis ES, Armstrong AJ, Calais J, Carducci MA, Dorff TB, Efstathiou JA, Gleave M, Gomella LG, Higoano C, Hope TA, Iagaru A, Morgans AK, Morris DS, Morris MJ, Petrylak DP, Reiter RE, Rettig MB, Ryan CJ, Sellinger SB, Spratt DE, Srinivas S, Tagawa ST, Taplin ME, Yu EY, Zhang T, McKay RR, Koo PJ, Crawford ED. Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. **Cancer**. 2024. PMID: 39616467.
35. Yu EY, Rumble BR, **Agarwal N**, Cheng HH, Eggener SE, Bitting RL, Beltran H, Giri VN, Spratt D, Mahal B, Lu K, Crispino T, Trabulsi EJ. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. **J Clin Oncol**. 2025. PMID: 39787437.
36. Carlsson SV, Barata PC, Bryce AH, George DJ, Gillessen S, Loeb S, Montgomery B, Morris D, Evensen C, Riaz I, Perez A, Palapattu G, Schoen MW, Washington S, Cornell B, Levine R, Aggarwal P, McGowan T, Cotter M, Thompson B, Devgan G, Russell D, Kuperman G, Lenero E, Iwata K, Miyahara AK, Soule HR, Carithers G, Oh WK, **Agarwal N**. Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer. **JCO Oncol Pract**. 2025. PMID: 40315399.

#### **D. Commentaries, Editorials, and Letters (Total: 81)**

1. Nordin TA, Hartz AJ, Noyes Jr R, Anderson MC, Rosenbaum ME, James PA, Ely JW, **Agarwal N**, Levy BT. Empirically identified goals for the management of unexplained symptoms. **Family Medicine**. 2006. PMID: 16823672.
2. **Agarwal N**, Gordeuk VR, Prchal JT. Are erythropoietin receptors expressed in tumors? Facts and Fiction; More Careful Studies Needed. **Journal of Clinical Oncology**. 2007. PMID: 17470878.
3. **Agarwal N**, Fletcher D, Ward JH. Obesity and Treatment of Prostate Cancer: What is the Right Dose of Lupron Depot? **Clinical Cancer Research**. 2007. PMID: 17606739.
4. Yoon D, **Agarwal N**, Prchal JT. Does Erythropoietin Promote Tumor Growth? **Clinical Cancer Research** 2008. PMID: 18347197.
5. **Agarwal N**, Nussenzveig RH, Swierczek SI, Parker CJ, Prchal JT. Does HUMARA assay for assessment of clonal hematopoiesis have shortcomings? **Blood**. 2009. PMID: 19745079.
6. **Agarwal, N**. Hormonal therapy use for prostate cancer and cardiovascular mortality in men. **Journal of American Medical Association (JAMA)**. 2010. PMID: 20051564.
7. **Agarwal N**. Editorial comment on “a Phase II Clinical Trial of Neoadjuvant Ketoconazole and Docetaxel Chemotherapy Prior to Radical Prostatectomy in High-Risk Patients”. **Journal of Urology**. 2011. PMID: 21791349.
8. **Agarwal N**, Dorff T, Goldkorn. New Prostate Cancer Drugs: Extending and Improving Life. **Lancet Oncology**. 2014. PMID: 25104108.

9. Pal SK, **Agarwal N**, Jones JO. Circulating tumor cells in prostate cancer: Does (nuclear) size matter? **Cancer**. 2015. PMID: 25980931.
10. Pal SK, **Agarwal N**, Grivas P, Choueiri T. Adjuvant Chemotherapy for Bladder Cancer: Using Population-Based Data to Fill a Void of Prospective Evidence. **Journal of Clinical Oncology**. 2016. PMID: 26786913.
11. **Agarwal N**, Shuch B, Pal SK. Up-front Targeted Therapy Prior to Cytoreductive Nephrectomy in Treatment-Naïve Patients With Metastatic Renal Cell Carcinoma. **JAMA Oncology**. 2016. PMID: 27254305.
12. Pal SK, **Agarwal N**. Kidney cancer: Finding a niche for girentuximab in metastatic renal cell carcinoma. **Nature Reviews Urology**. 2016. PMID: 27349371.
13. Pal SK, Karam JA, Bergerot P, **Agarwal N**. Developing a Clear Path Forward for NonClear-Cell Renal Carcinoma. **Journal of Clinical Oncology**. 2016. PMID: 27601540.
14. Pal SK, **Agarwal N**, Dizman N, Sonpavde G. Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar. **Lancet Oncology**. 2016. PMID: 27720137.
15. Penson DF, Armstrong AJ, Concepcion R, **Agarwal N**, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoschik A, Phung, Higano CS. Reply to M.A.N. Sendur et al and J. Michels. **Journal of Clinical Oncology**. 2017. PMID: 28034066.
16. Pal SK, Maia MC, Dizman N, **Agarwal N**. Subset Analyses from CheckMate 025: A Challenge to Current Clinical Dogma? **European Urology**. 2017. PMID: 28314610.
17. Gill DM, Sonpavde G, Pal SK, **Agarwal N**. Which checkpoint inhibitor? An embarrassment of riches for bladder cancer. **Journal of Immunotherapy**. 2017. PMID: 28472906.
18. Shuch B, Hahn AW, **Agarwal N**. Current Treatment Landscape of Advanced Papillary Renal Cancer. **Journal of Clinical Oncology**. 2017. PMID: 28737973.
19. Maia MC, Yang ES, **Agarwal N**, Pal SK. A step towards predicting checkpoint inhibitor response in kidney cancer. **Lancet Oncology**. 2017. PMID: 28759367.
20. Bergerot P, **Agarwal N**, Pal SK, Jones JO. Sarcomatoid Renal Cell Carcinoma: The Apple Doesn't Fall Far From the Tree. **Clinical Cancer Research**. 2017. PMID: 28912138.
21. Hahn AW, Nussenzveig RH, Pal SK, **Agarwal N**. Blood-and tissue-based tumor genomics: a battle royale or match made in heaven? **Annals of Oncology**. 2017. PMID: 28945831.
22. Hahn AW, Pal SK, **Agarwal N**. HSD3B1-A Predictive Biomarker in Advanced Prostate Cancer. **JAMA Oncology**. 2017. PMID: 29049481.
23. Maia MC, Grivas P, **Agarwal N**, Pal SK. Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions. **European Urology**. 2018. PMID: 29097099.
24. **Agarwal N**, Lanman RB, Pal SK. Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. **JAMA Oncology**. 2018. PMID: 30027290.
25. Hahn AW, Pal SK, **Agarwal N**. Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome. **The Oncologist**. 2018. PMID: 30139834.
26. Tripathi A, **Agarwal N**. Editorial Comment. **The Journal of Urology**. 2018. PMID: 30189185.
27. **Agarwal N**, Nussenzveig R, Pal SK. Biomarkers in renal-cell carcinoma: building on clinical paradigms. **Lancet Oncology**. 2018. PMID: 30416074.

28. Swami U, Grivas P, **Agarwal N**. The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial Carcinoma. **The Oncologist**. 2019. PMID: 30926675.
29. Swami U, Nussenzveig RH, Haaland B, **Agarwal N**. Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement. **Annals of Translational Medicine**. 2019. PMID: 31032299.
30. Swami U, Pal SK, **Agarwal N**. Ideal Glucocorticoid Regimen With Abiraterone Acetate: Options and Challenges. **JAMA Oncology**. 2019. PMID: 31246246.
31. Pal SK, Swami U, **Agarwal N**. Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How. **European Urology**. 2019. PMID: 31300236.
32. Pal S, Hu-Lieskovan S, **Agarwal N**. Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumors? **Lancet Oncology**. 2019. PMID: 31563518.
33. Hahn AW, Pal SK, **Agarwal N**. Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma. **The Oncologist**. 2019. PMID: 32162830.
34. Tripathi A, Lin E, **Agarwal N**. Biomarkers in metastatic renal cell carcinoma in the era of immune checkpoint inhibitors. **Annals of Translational Medicine**. 2019. PMID: 31656782.
35. Swami U, Yap JT, **Agarwal N**. Radioisotope Imaging and Therapy for Bone Metastasis in Men With Castration-Resistant Prostate Cancer. **JAMA Oncology**. 2019. PMID: 31830203.
36. Hahn AW, **Agarwal N**. The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas. **Cancer Treatment and Research Communications**. 2020. PMID: 32679555.
37. Khaki AR, **Agarwal N**, Pal SK, Grivas P. Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest. **Cancer**. 2020. PMID: 32757318.
38. Swami U, Nussenzveig RH, **Agarwal N**. Quest for Ideal Composite Biomarkers for Response to Immunotherapies. **Clinical Cancer Research**. 2020. PMID: 32759359.
39. Tripathi A, McFarland T, **Agarwal N**. PARP Inhibitors in Prostate Cancer: A Promise Delivered. **European Urology Oncology**. 2020. PMID: 32893185.
40. Meza L, Bergerot PG, **Agarwal N**, Pal SK. Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe. **Annals of Oncology**. 2020. PMID: 33121996.
41. Hwang JK, **Agarwal N**, Brugarolas J, Zhang T. Checking the Hippo in sarcomatoid renal cell carcinoma with immunotherapy. **Clinical Cancer Research**. 2020. PMID: 33106290.
42. Swami U, Antonarakis ES, **Agarwal N**. Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. *Eur Urol* 2020, 78:652-6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer. **European Urology**. 2021. PMID: 33419681.
43. Hahn AW, Bilen MA, **Agarwal N**. Successful Recruitment of Black Men to Prostate Cancer Clinical Trials-A Lesson in Achievement. **JAMA Network Open**. 2021. PMID: 33496790.

44. Coletta AM, Sayegh N, **Agarwal N**. Body composition and metastatic prostate cancer survivorship. **Cancer Treatment and Research Communications**. 2021. PMID: 33517236.
45. Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, **Agarwal N**, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V; COVID19 and Cancer Clinical Trials Working Group. Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. **Nature Reviews Clinical Oncology**. 2021. PMID: 33758378.
46. Sanchez A, **Agarwal N**. Quantifying the Costs of Care Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated in the Veterans Health Administration. **JAMA Network Open**. 2021. PMID: 33787916.
47. Koh MY, Sayegh N, **Agarwal N**. Seeing the forest for the trees-single-cell atlases link CD8+ T cells and macrophages to disease progression and treatment response in kidney cancer. **Cancer Cell**. 2021. PMID: 33861995.
48. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, **Agarwal N**, Jonasch E, Koh MY. Correction: Macrophage HIF-1 $\alpha$  Is an Independent Prognostic Indicator in Kidney Cancer. **Clinical Cancer Research**. 2021. PMID: 34074655.
49. Giannarini G, **Agarwal N**, Apolo AB, Briganti A, Grivas P, Gupta S, Kamat AM, Montorsi F, Rouprêt M, Necchi A. Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer. **European Urology Oncology**. 2021. PMID: 34147473.
50. Sayegh N, **Agarwal N**, Swami U. Drug Development for Prostate Cancer with Biochemical Recurrence: Trials and Tribulations. **European Urology Oncology**. 2021. PMID: 34148857.
51. **Agarwal N**, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Özgüroğlu M, Soto AJ, Merseburger AS, Uemura H, Ye D, Given R, Basch E, Miladinovic B, Lopez-Gitlitz A, Chi KN. Reply by Authors. **The Journal of Urology**. 2021. PMID: 34296946.
52. Tripathi N, **Agarwal N**, Tripathi A. Nature versus Nurture: Investigating Racial Disparity in Advanced Prostate Cancer. **The Oncologist**. 2021. PMID: 34333836.
53. Swami U, **Agarwal N**. Editorial Comment. **The Journal of Urology**. 2021. PMID: 34455827.
54. Hahn AW, George DJ, **Agarwal N**. An Evolving Role for AXL in Metastatic Renal Cell Carcinoma. **Clinical Cancer Research**. 2021. PMID: 34598944.
55. Swami U, **Agarwal N**. Drug development in metastatic prostate cancer: lessons from ACIS. **Lancet Oncology**. 2021. PMID: 34600603.
56. Swami U, Sayegh N, **Agarwal N**. Development of Novel Regimens Combining Immune Checkpoint Inhibitors and Radiation Therapy in Prostate Cancer. **European Urology**. 2021. PMID: 34895788.
57. Schmidt B, **Agarwal N**. Black Men Receiving Radiotherapy for Localized Prostate Cancer Have Improved Outcomes-Clinical Trial Access or Racial Advantage? **JAMA Network Open**. 2021. PMID: 34964857.

58. Penson DF, Armstrong AJ, Concepcion RS, **Agarwal N**, Olsson CA, Karsh LI, Dunshee CJ, Duggan W, Shen Q, Sugg J, Haas GP, Higano CS. Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. **Prostate Cancer and Prostatic Diseases**. 2021. PMID: 34848822.
59. Morgan G, **Agarwal N**, Choueiri TK, Dizon DS, Hamilton EP, Markham MJ, Lewis M, Prowell TM, Rugo HS, Subbiah V, West HL. The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. **Cancer Discovery**. 2022. PMID: 35791692.
60. Guha A, Sayegh N, **Agarwal N**. Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies. **JACC CardioOncology**. 2022. PMID: 35818554.
61. Azad AA, Kostos L, **Agarwal N**. KIT as a therapeutic target in neuroendocrine prostate cancer. **Cancer Cell**. 2022. PMID: 36332623.
62. Sahu KK, **Agarwal N**. J Urol. Editorial Comment. **The Journal of Urology**. 2023. PMID: 36484444.
63. Stabellini N, Cullen J, Moore JX, Cao L, **Agarwal N**, Hamerschlag N, Waite K, Montero AJ, Barnholtz-Sloan JS, Guha A. Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer. **JACC CardioOncology**. 2022. PMID: 36909936.
64. Gebrael G, Thomas VM, Swami U, **Agarwal N**. The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice. **The Oncologist**. 2023. PMID: 37014098.
65. Gebrael G, Fortuna GG, **Agarwal N**. Developing an Ideal Risk Stratification Model for Metastatic Renal Cell Carcinoma. **JAMA Oncology**. 2023. PMID: 37347470.
66. Campbell P, Gebrael G, **Agarwal N**. Racial Disparities and Molecular Insights in Translocation Renal Cell Carcinoma: Advancing Understanding and Treatment Approaches. **The Oncologist**. 2023. PMID: 37597001.
67. Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, Li H, Sahu KK, Srivastava A, McFarland T, Maughan BL, Swami U, **Agarwal N**. Correction: Survival outcomes of real-world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors. **Prostate Cancer and Prostatic Diseases**. 2023. PMID: 37620429.
68. Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Thomas VM, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, **Agarwal N**, Swami U, Maughan BL. Reply by Authors. **Urology Practice**. 2023. PMID: 37903752.
69. Narang A, **Agarwal N**. Editorial Comment. **Urology Practice**. 2024. PMID: 38117973.
70. Hage Chehade C, Gebrael G, **Agarwal N**. Bispecific T-cell Engagers in Metastatic Castration-Resistant Prostate Cancer. **Cancer Discovery**. 2024. PMID: 38213299.
71. Fizazi K\*, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, **Agarwal N\*** (\*equal contribution). Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. **Nature Medicine**. 2024. PMID: 38297094.

72. Mathew Thomas V, Grivas P, **Agarwal N**. Gemcitabine with cisplatin and nivolumab: Redefining standard of care for first-line metastatic urothelial carcinoma? **Med.** 2024. PMID: 38340704.
73. Hage Chehade C, **Agarwal N**. Molecular subtypes as potential biomarkers in renal cell carcinoma. **Cancer Cell.** 2024. PMID: 38670092.
74. Hage Chehade C, Ozay ZI, **Agarwal N**. Targeting the FGFR Pathway in Patients with Advanced Solid Tumors. **Clinical Cancer Research.** 2024. PMID: 39115427.
75. Hage Chehade C, Ozay ZI, **Agarwal N**, Swami U. Correlating Prostate-specific Antigen Dynamics with Outcomes of Lutetium-177-PSMA-617 Treatment: Refining Predictive and Prognostic Biomarkers. **European Urology.** 2024. PMID: 39317634.
76. Hage Chehade C, Gebrael G, **Agarwal N**. [89Zr]Zr-girentuximab PET-CT imaging to diagnose, characterize, and differentiate clear-cell renal cell carcinoma. **Med.** 2024. PMID: 39520979.
77. Hage Chehade C, **Agarwal N**. Racial and Ethnic Disparities in Prostate Cancer- Correlation With Incidence and Progression. **JAMA Network Open.** 2024. PMID: 39546316.
78. Ozay ZI, Hage Chehade C, **Agarwal N**, Swami U. Assessing Nectin-4 as a Predictive Biomarker in Urothelial Carcinoma and Other Genitourinary Malignancies. **JCO Precision Oncology.** 2024. PMID: 39693590.
79. Ozay ZI, Chehade CH, **Agarwal N**. On-treatment PSA kinetics as a potential biomarker: Guiding personalized treatment in metastatic hormone-sensitive prostate cancer. **Med.** 2025. PMID: 39954667.
80. Ozay ZI, Swami U, **Agarwal N**. Challenges in the Management of Advanced Prostate Cancer. **JCO Oncol Pract.** 2025. PMID: 40014837.
81. Ozay ZI, **Agarwal N**. Race, Ethnicity, and Tumor Genomic Testing in Prostate Cancer. **JAMA Netw Open.** 2025. PMID: 40354059.

#### **E. Case Report Articles (Total: 16)**

1. Sharma SK, Dey AB, **Agarwal N**, Nagarkar KM, Gujral S. Tuberculosis: A rare cause of splenic abscess. **Journal of Association of Physician India.** 1999. PMID: 10778602.
2. **Agarwal N**, Cherascu B. Concomitant acral necrosis and hemolytic uremic syndrome following ingestion of quinine. **Journal of Postgraduate Medicine.** 2002. PMID: 12432194.
3. **Agarwal N**, Klix M, Burns CP. Successful management with intravenous immunoglobulins of acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance. **Annals of Internal Medicine.** 2004. PMID: 15238389.
4. **Agarwal N**, Tepe E, Mishra A, Ward JH. Relapse of acute promyelocytic leukemia presenting as granulocytic sarcoma in the hip. **Annals of Hematology.** 2006. PMID: 16718497.
5. **Agarwal N**, Spahr JE, Rodgers GM. Successful management of intra-abdominal hemorrhage in presence of severe alcoholic liver disease with activated recombinant factor VII (NovoSeven)". A case report and review of the literature on approved and off label use of recombinant activated factor VII (rFVIIa). **Blood Coagulation and Fibrinolysis.** 2007. PMID: 17287641.
6. Agarwal AM, **Agarwal N**, Glenn MJ, Lim MS. Blastic Transformation of Low Grade Follicular Lymphoma. **Journal of Clinical Oncology.** 2007. PMID: 17538181.

7. Wada D, **Agarwal N**, Florell S, Lim, MS. Recurrent squamous cell carcinoma and follicular lymphoma arising in the scalp after treatment for lymphoma. **Pathology** 2008. PMID: 18428060.
8. Chen A, **Agarwal N**. Reversible Posterior Leukoencephalopathy Syndrome Associated with Sunitinib. **Internal Medicine Journal**. 2009: 39(5): 341-2. PMID:19382984
9. Lim HY, Agarwal AM, **Agarwal N**, Ward JH. Recurrent Epistaxis as a Presenting Sign of Androgen-Sensitive Metastatic Prostate Cancer. **Singapore Medical Journal** 2009. PMID: 19495504.
10. Narayanan S, Duffin KC, Batten J, **Agarwal N**. Improvement of Psoriasis during Sunitinib Therapy for Renal Cell Carcinoma. **American Journal of Medical Sciences**. 2010. PMID: 20421784.
11. Sangle N, Mao R, Shetty S, Schiffman J, Dechet C, Layfield L, **Agarwal N**, Liu T. Novel molecular aberrations and pathologic findings in tubulocystic variant of renal cell carcinoma. **Indian Journal of Pathology & Microbiology**. 2013. PMID: 24441240.
12. Merriman J, Tward J, Albertson D, Dechet C, **Agarwal N**. Durable Response to Treatment With Combination Radiotherapy and High-dose Interleukin-2 in Metastatic Chromophobe Variant Renal Cell Carcinoma. **Journal of Immunotherapy**. 2016. PMID: 26849079.
13. Smith-Cohn MA, Gill D, Voories BN, **Agarwal N**, Garrido-Laguna I. Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. **Immunotherapy**. 2017. PMID: 28877632.
14. Rathi N, Anderson N, Greenberg S, Vagher J, **Agarwal N**, Hahn AW. DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC). **World Journal of Oncology**. 2018. PMID: 30220950.
15. McComas K, **Agarwal N**, Bowen G, Maughan BL, Tward JD. Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. **Clinical Genitourinary Cancer**. 2020. PMID: 32335061.
16. McFarland TR, Tandar CE, **Agarwal N**, Swami U. Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report. **Cancer Treatment and Research Communications**. 2021. PMID: 34700141.

#### **F. Trials in Progress and Plain Language Summary Articles (Total: 10)**

1. **Agarwal N**, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghrou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. **Future Oncology**. 2022. PMID: 35034502.
2. **Agarwal N\***, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliogy M, Lin X, Czibere A, Fizazi K\* (**\*equal contribution**). Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. **Future Oncology**. 2022. PMID: 35080190.
3. **Agarwal N\***, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliogy M, Lin X, Czibere A, Fizazi K\* (**\*equal contribution**). Plain

- language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer. **Future Oncology**. 2022. PMID: 35950899.
4. **Agarwal N**, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen HC, Lanzalone S, Niyazov A, Fizazi K. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. **Future Oncology**. 2023. PMID: 37882449.
  5. Coletta AM, Simon LH, Maslana K, Taylor S, Larson K, Hansen PA, Thomas VM, Ulrich CM, Kohli M, Chipman J, Swami U, Gupta S, Maughan BL, **Agarwal N**. Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial. **BMC Cancer**. 2024. PMID: 38637770.
  6. **Agarwal N\***, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, Giorgi U, Joung JY, C Fong PC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Santo ND, Zohren F, Fizazi K\* (**\*equal contribution**). Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer. **Future Oncology**. 2024. PMID: 38995237.
  7. Karsh LI, Bevans KB, Saad F, Chung BH, Oudard S, Brookman-May SD, McCarthy SA, Smith MR, Chi KN, Small EJ, **Agarwal N**. Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies. **Future Oncology**. 2024. PMID: 39163505.
  8. **Agarwal N**, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen HC, Lanzalone S, Niyazov A, Fizazi K. The TALAPRO-3 study design: a plain language summary. **Future Oncology**. 2024. PMID: 39451095.
  9. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, **Agarwal N**. Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study. **Future Oncol**. 2025. PMID: 39882687.
  10. George DJ, **Agarwal N**, Ramaswamy K, Klaassen Z, Bitting RL, Russell D, Sandin R, Emir B, Yang H, Song W, Lin Y, Hong A, Gao W, Freedland SJ. Plain language summary: does race or income status affect the cancer treatments that patients with metastatic castration-sensitive prostate cancer (mCSPC) receive in the United States? **Future Oncol**. 2025. PMID: 40277241.

**Abstracts/Poster Presentations (Total: 482)**

<https://neerajagarwal.me/oralpresentations/>

**Book Chapters/Other Reviews (Total: 13) and Web Based Publications**

<https://neerajagarwal.me/book-chapters-web-based-publications/>